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ABSTRACT""
Chronic"wounds" and"wounds" that" are" difficult" to" heal" are" a"major" concern" for"Australian"healthcare"expenditure"and"a" source"of"misery" for" those"who" suffer"from"them.""For"example,"in"Australia"in"2012,"there"were"an"estimated"433,000"people"suffering"from"these,"costing"an"estimated"AUD2.6"billion"dollars"for"the"year"to"July." "Novel"ways"of"healing"wounds"are"continually"being"sought." "Two"strategies" used" to" accelerate" wound" healing" are" augmenting" angiogenesis" and"through" manipulation" of" wound" healing" growth" factors." " The" method" of"stimulating" angiogenesis" proposed" in" this" research" was" through" the" use" of" a"topically"applied"flavonoid"or"lignan"molecule.""Two"compounds"in"particular,"the"lignan" erythroZguaiacylglycerolZ8ZOZ4’Zconiferyl" alcohol" (T1)" and" the" flavonoid"naringenin,"have"demonstrated"proZangiogenic"activity"based"on" in#vitro" testing"but"they"had"not"been"trialled"previously"in#vivo.""""C57BL/6J"mice"were"used" in" techniques"building"on"previous" studies."Wounds"were" created"with" a" control," positive" control," and" T1" and" naringenin" topically"applied"at"varying"concentrations.""The"compounds"tested"were"applied"at"3Zday"intervals,"aiming"for"wound"healing"within"12"days.""A"second"group"was"used"to"analyse"the"wounds"and"compounds"trialled"at"day"3"after"wounding,"the"day"of"maximal"angiogenesis.""The"wounds"were"recorded"and"measured"using"pictorial"and"digitalZimage"analysis.""Results"showed"that"both"the"flavonoid"(naringenin)"and" the" lignan" (T1)"when" applied" to"wounds" actually" increased" the" size" of" the"
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wounds" and" the" length" of" time" required" for" the" wounds" to" heal." " Subsequent"histological"analysis"revealed"that"wounds"treated"with"both"T1"and"naringenin,"although"not"healing"faster,"produced"higher"amounts"of"granulation"tissue"and"collagen" deposition." " Based" on" these" data" it" is" hypothesised" that" the" above"compounds" caused" an" excessive" deposition" of" granulation" tissue," preventing"effective" wound" healing." " Although" the" wounds" did" not" heal" effectively," the"results"obtained"from"this"study"may"be"useful"when"applied"to"wounds"that"are"difficult"and"slow"to"heal,"such"as"diabetic"ulcers.""In" conclusion," further" studies" are" required" to" confirm" that" these" novel"compounds" increase" angiogenesis," granulation" tissue" and" collagen" deposition"within"wounds.""If"so,"new"studies"to"find"optimal"dosage"and"application"regimes"may"provide"useful"approaches"to"accelerating"wound"healing"in"the"future."""""""""""""""
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Chapter)1:)Introduction)
1.1)Costs)and)Implications)of)Impaired)Wound)Healing:)Caring" for" those" who" suffer" from" both" acute" and" chronic" wounds" comes" at" a"considerable"cost"for"annual"Australian"healthcare"expenditure.""For"example,"in"Australia" in" 2012–13" there" were" an" estimated" 433,000" people" suffering" from"acute" and" chronic"wounds," costing" an" estimated"AUD2.6" billion" dollars" for" the"year"to"July.(1)""This"estimated"cost"only"takes"into"account"the"cost"of"healthcare"related"treatment"and"professional"expenses." "It"does"not"calculate"the"real"cost"placed" on" an" individual’s" quality" of" life" as" they" may" not" be" able" to" work" or"contribute" fully" to" their" community;" or" they"may" require" communityZbased" or"outpatient"healthcare" services"or"additional"help" for" those" required" to" care" for"debilitated" family" and" friends." " This" calculation" also" does" not" allow" for" the"potential" adverse" effects" that" may" followZon" from" difficult" or" nonZhealing"wounds." " So" significant" is" this" problem" in" Australian" Society" that" a" Federal"Government" initiative," the" Wound" Management" Innovation" CRC," has" been"developed" to" deal"with" this" issue.(1)""Similar" issues" and" initiatives" plague" other"Western" nations" such" as" the" United" States," where" an" estimated" USD25" billion"dollars" are" spent" annually" on" chronic" and" difficult" to" heal" wounds" with" an"estimated" 6.5" million" people" currently" suffering.(2)" " Correspondingly," in" the"United"Kingdom," the"2005–06" cost" for" chronic"wounds"was"GBP2.3–3.1"billion"pounds"with" an" estimated"200,000" sufferers.(3)" "However," these" figures" do"not"include"the"significant"number"of"patients"who"may"be"lost"to"followZup.(4)""The" Australian" Wound" Management" Innovation" CRC" has" been" specially"
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developed" as" a" multiZdisciplinary" healthcare" research" model" employing" three"main"arms"of"research,"with"the"enabling"of"new"technologies,"clinical"application"and" tools" and" therapies," all" with" a" view" to" transforming" wound" outcomes.(1)""Major" outcome" points" addressed" by" the" Australian" Wound" Management"Innovation" CRC" are" in" the" areas" of" accelerating" healing," preventing" wound"infection" and" reducing" scar" formation" in" acute" wounds.(1)" " Currently," of" the"research" initiatives" being" investigated" at" the" Wound" Management" Innovation"CRC," topical" compounds" utilising" naturallyZoccurring" flavonoidZbased"compounds"with"a"view"of"accelerating"wound"blood"vessel" (neoZangiogenesis)"formation"are"not"being"trialled.""Likewise,"there"is"currently"very"little"published"on" the" potential" healing" properties" of" flavonoidZbased" compounds" throughout"the"literature."With"all"problems"faced"in"scientific"and"medical"endeavour,"novel"therapies" and" solutions" are" always" being" sought." " Early" in.vitro" research"performed"at"the"John"Curtin"School"of"Medical"Research"concerning"flavonoidZ"and" lignanZbased" compounds" has" shown" that" some" possess" the" ability" to"increase"angiogenesis." "Thus,"one"proZangiogenic"compound"from"each"of" these"classes" of" compounds" forms" the" basis" of" the" novel" wound" healing" strategies"detailed"in"this"thesis.""Chronic"wounds," as"mentioned" above," are" a" serious" hindrance" to" patients" and"healthcare" providers," and" expenditure" alike." " However," when" wounds" are"coupled"with"diabetes"they"become"an"even"more"difficult,"expensive"and"timeZconsuming" enterprise." " Difficult" and" nonZhealing" diabetic" leg" ulcers" are" a"significant"health"problem"for"sufferers"and"add"considerable"cost"to"Australian"healthcare" expenditure" annually." " Direct" health" expenditure" for" diabetes" was"
14""
estimated" at" AUD989" million" in" 2004–05" and" with" an" ageing" population" and"rising"prevalence"of"diabetes,"novel"methods"of"treatment"are"crucially"needed.(5)""For" example," the" calculated" cost" of" conventional" ulcer" healing" treatments" in"2002"for"an"open,"uninfected"ulcer"was"AUD182"for"the"first"week"and"AUD81"for"every"week" thereafter." " For" an" ulcer"with" a" superficial" infection," the" cost" was"AUD369" for" the" first"week"and"AUD217" for"every"subsequent"week." "However,"for"an"ulcer"with"a"deep"infection,"the"initial"cost"of"treatment"was"AUD2937"for"the"first"week"and"AUD2881"for"each"subsequent"week.(6)""These"costs"were"also"calculated"in"2002"and"expenses"would"have"surely"increased"since"then.""These"calculations"again"do"not"measure" the" intangible"effects"on"a"patient’s" lifestyle,"personal"finances"and"family.""There"is"also"an"immediate"need"to"find"new"solutions"to"this"problem,"especially"with" regard" to" Indigenous" Australians." " Indigenous" Australians" suffer" diabetes"and"ulcer"complications"at"rates"greater"than"three"times"that"of"NonZindigenous"Australians.(7)" " Indigenous" Australians" with" diabetes" are" also" 10.3" times" more"likely"to"be"hospitalised"with"limb"ulcer"complications"and"7.3"times"more"likely"to" die" from" limb" ulcer" complications.(7)" " Indigenous" Australians"with" advanced"diabetes" also" suffer" rates" of" gangrene" 100" times" more" readily" than" the" nonZdiabetic"population.(8)""Due"to"the"multifactorial"pathological"process"of"diabetes,"lower" limb" atherosclerosis" is" hastened," leading" to" gangrene" at" an" accelerated"rate,"often"ending" in" the"requirement" for"amputation." "The"costs"of"amputation"and"more"importantly"the"costs"of"rehabilitation"and"social"security"required"for"amputees"are"not"readily"available,"but"as"could"be"logically"reasoned,"are"a"very"significant"expense."
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For"example,"it"is"recommended"that"individuals"be"followedZup"every"3"months"after" amputation" and" require" a" rehabilitation" duration" of" 18" months" with"physician" followZup" every" 6" months." " This" does" not" calculate" the" cost" of" preZamputation"planning,"preZprosthetic,"prosthesis"cost"and"postZoperative"surgical"complications" such" as" delayed" wound" healing" and" phantom" limb" pain.(9," 10)""Complications" from"diabetic" foot"are" the"most"common"cause"of"nonZtraumatic"foot" amputation" in" industrialised" nations" and" account" for" 25%" of" all" diabetic"admissions"in"the"United"States"and"Great"Britain.(11)""The"ageZstandardised"minor"and"major"amputation"rates"for"Indigenous"Western"Australians" after" the" age" of" 50" years" per" 100,000" population" is" 185" and" 76.8"respectively." " Compared" to" NonZindigenous" Australians," the" rates" per" 100,000"population"after"50"years"of"age"for"minor"and"major"amputations"are"28.9"and"13.1" respectively.(12)""It"must" also"be" acknowledged" that" the" above" rate" of" 76.8"per"100,000"would"be"significantly"higher"except"for"the"fact"that"Indigenous"life"expectancy" is" considerably" shorter" than" nonZIndigenous." " For" example,"Indigenous"males"and"females"have"life"expectancies"of"59.4"years"and"64.8"years"respectively.""This"is"significantly"shorter"than"nonZIndigenous"life"expectancies,"which"are"78.7"years"and"83.5"years"respectively.(13,"14)"""Solutions" for" these" problems" are" desperately" needed." " The" current," traditional"methods" of" wound" care" are" not" sufficient" for" the" demand" placed" upon" them.""Also,"with"an"ageing"population,"better"approaches"to"wound"care"are"required.""For"example," in"1970–71,"Australians"aged"over"65"years"comprised"8%"of" the"population," climbing" to" 13%" in" 2001–02." " In" the" next" 40" years" this" figure" is"
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expected"to"double"to"25%,"with"no"growth"in"the"workforce"population.(15)""The"most" appropriate," novel" therapeutic" intervention" for" wound" treatment" and"subsequent"ulcer"prevention"needs"to"be"inexpensive,"readily"available,"topically"applied"by"either"personnel"requiring"minimal" training"or" the"patient" themself,"and"produce"reliable,"reproducible"and"safe"healing.""Due"to"financial"constraints"on" the" healthcare" system" and" the" chronic" nature" of"wounds" and" diabetes" it" is"vital"that"this"intervention"be"provided"in"the"primary"healthcare"setting.""Other" important"aspects"of"wound"healing"are"those"such"as"age,"sex,"nutrition,"vitamin" and" trace" elements," drugs," systemic" disease," hypoxia," wound" blood"supply," infection," foreign" bodies" and" surgical" technique.(16,"17)" " It" is" beyond" the"scope"of"this"thesis"to"discuss"all"aspects"of"wound"healing;"however"basic"wound"healing"concepts"and"pathologies"of"relevance"will"be"reviewed.""
1.2:)Pressure)Ulcer)Pathology:)Not"only"are"solutions"for"post"pressure"ulcer"occurrence"being"investigated,"but"also"preZemptive" initiatives"are"being"used" in"an"attempt" to" reduce" the"burden"that" these" chronic"wounds" cause." " For" example,"wound" screening" is" a" concept"designed" to" try" and" predict" those" at" risk" of" developing" wound" complications."Examples" of" clinical" predictive" thinking" in" preventing" pressure" sore" and" ulcer"development" include" both" the" Braden" Scale" (US)" and" Waterlow" Score" (UK)"(Tables"1"and"2"overleaf).(18Z20)""
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"Table"1:"Braden"Scale"for"Predicting"Pressure"Sore"Risk.(21)"" "
"Table"2:"Waterlow"Pressure"Ulcer"Prevention/Treatment"Policy.(22)"
BRADEN SCALE FOR PREDICTING PRESSURE SORE RISK 
 
Patient=s Name _____________________________________    Evaluator=s Name________________________________                                                   Date of Assessment    
 
 
 
 
 
 
 
 
 
SENSORY PERCEPTION 
 
ability to respond meaning- 
fully to pressure-related 
discomfort 
 
 
1. Completely Limited 
Unresponsive (does not moan, 
flinch, or grasp) to painful 
stimuli, due to diminished level of 
con-sciousness or sedation. 
                OR 
limited ability to feel 
pain over most of body  
 
2. Very Limited 
Responds only to painful 
 stimuli.  Cannot communicate 
 discomfort except by moaning 
 or restlessness 
              OR 
has a sensory impairment which 
limits the ability to feel pain or 
discomfort over 2 of body. 
 
 
3. Slightly Limited 
Responds to verbal com- 
mands, but cannot always 
communicate discomfort or the 
need to be turned. 
                  OR 
has some sensory impairment 
which limits ability to feel pain  
or discomfort in 1 or 2 extremities. 
 
4. No Impairment 
Responds to verbal 
commands.  Has no 
sensory deficit which would 
limit ability to feel or voice 
pain or discomfort.. 
 
 
 
 
 
 
 
 
 
MOISTURE 
 
degree to which skin is  
exposed to moisture 
 
1. Constantly Moist 
Skin is kept moist almost 
constantly by perspiration, urine, 
etc.  Dampness is detected 
every time patient is moved or 
turned. 
 
 2.  Very Moist 
Skin is often, but not always moist.  
Linen must be changed at least 
once a shift. 
 
3.  Occasionally Moist: 
Skin is occasionally moist, requiring 
an extra linen change approximately 
once a day. 
 
4.  Rarely Moist 
Skin is usually dry, linen 
only requires changing at 
routine intervals. 
 
 
 
 
 
 
 
 
 
ACTIVITY 
 
degree of physical activity 
 
1.  Bedfast 
Confined to bed. 
 
2.  Chairfast 
Ability to walk severely limited or 
non-existent.  Cannot bear own 
weight and/or must be assisted into 
chair or wheelchair. 
 
3.  Walks Occasionally 
Walks occasionally during day, but 
for very short distances, with or 
without assistance.  Spends 
majority of each shift in bed or chair 
 
4.  Walks Frequently 
Walks outside room at least 
twice a day and inside room 
at least once every two 
hours during waking hours 
 
 
 
 
 
 
 
 
 
MOBILITY 
 
ability to change and control  
body position 
 
1. Completely Immobile 
Does not make even slight 
changes in body or extremity 
position without assistance 
 
2.  Very Limited   
Makes occasional slight changes in 
body or extremity position but 
unable to make frequent or 
significant changes independently. 
 
3. Slightly Limited 
Makes frequent though slight 
changes in body or extremity 
position independently. 
 
4.  No Limitation 
Makes major and frequent 
changes in position without 
assistance. 
 
 
 
 
 
 
 
 
 
NUTRITION 
 
usual food intake pattern 
 
1. Very Poor 
Never eats a complete meal. 
Rarely eats more than a of any 
food offered.  Eats 2 servings or 
less of protein (meat or dairy 
products) per day.  Takes fluids 
poorly.  Does not take a liquid 
dietary supplement 
                    OR 
is NPO and/or maintained on 
clear liquids or IV=s for more 
than 5 days. 
 
2. Probably Inadequate 
Rarely eats a complete meal and 
generally eats only about 2 of any 
food offered.  Protein intake 
includes only 3 servings of meat or 
dairy products per day.  
Occasionally will take a dietary 
supplement. 
                   OR 
receives less than optimum amount 
of liquid diet or tube feeding 
 
3.  Adequate 
Eats over half of most meals.  Eats 
a total of 4 servings of protein 
(meat, dairy products per day.  
Occasionally will refuse a meal, but 
will usually take a supplement when 
offered 
                  OR 
is on a tube feeding or TPN 
regimen which probably meets 
most of nutritional needs 
 
4.  Excellent 
Eats most of every meal.  
Never refuses a meal.  
Usually eats a total of 4 or 
more servings of meat and 
dairy products.  
Occasionally eats between 
meals.  Does not require 
supplementation. 
 
 
 
 
 
 
 
 
 
FRICTION & SHEAR 
 
 
1. Problem 
Requires moderate to maximum 
assistance in moving.  Complete 
lifting without sliding against 
sheets is impossible.  Frequently 
slides down in bed or chair, 
requiring frequent repositioning 
with maximum assistance.  
Spasticity, contractures or 
agitation leads to almost 
constant friction 
 
2. Potential Problem 
Moves feebly or requires minimum 
assistance.  During a move skin 
probably slides to some extent 
against sheets, chair, restraints or 
other devices.  Maintains relatively 
good position in chair or bed most 
of the time but occasionally slides 
down. 
 
3.  No Apparent Problem 
Moves in bed and in chair 
independently and has sufficient 
muscle strength to lift up 
completely during move.  Maintains 
good position in bed or chair. 
 
 
 
 
 
 
 
 
 
 
 
  8 Copyright Barbara Braden and Nancy Bergstrom, 1988   All rights reserved                                                                                                                                      Total  Score 
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Pressure" ulcers" are" also" known" as" bedsores" or" decubitus" (lying" down)" ulcers.""Pressure" ulcers" are" caused" by" the" persistence" of" pressure" placed" on" bony"prominences"whilst" the"person" is" lying"down"and"not"moving." "Pressure"ulcers"are"not"a"new"phenomenon;" initial"descriptions"began" in"ancient"Egypt"around"3000BC,"but"gained"formal"description"in"a"scientific"sense"in"1593"by"Fabricius"Hildanus"who"described"them"as"Gangraena.(23,"24)" "Further"distinction"between"outcome" and" pathogenesis" was" postulated" by" Wohlleben" in" 1777" when" he"referred" to" this" phenomenon" as" Gangraena# per# decubitum," literally" tissue"necrosis" by" lying" down.(23)" "However," much" of" the" current" understanding" and"published" literature" has" come" postZWorld" War" 2" with" the" advent" of" mass"immobilised"casualties.(24)""
"Pressure"ulcers,"however,"cannot"be"viewed"alone"in"the"context"of"immobility"–"they"are"a"serious"complication"of"multiZmorbidity"as"well.(25)""Other"factors"such"as"urinary"and"faecal"incontinence,"diabetes"mellitus"and"difficulty"with"feeding"have" also" been" found" to" be" statistically" signification" in" the" development" of"pressure" ulcers.(24," 26," 27)" " Malnutrition" and" poor" circulation" (leading" to" tissue"hypoperfusion)" secondary" to" clinical" entities" such" as" reduced" oral" intake" and"congestive" heart" failure" are" particularly" relevant" –" conditions" that" are" highly"prevalent"in"the"elderly,"inpatient"population.(25,"28)"
"The"identification"of"pressure"ulcer"risk"factors"has"led"to"preventative"strategies"by" assessing" risk" early," by" use" of" the" Braden" and" Waterlow" Scales," however,"unfortunately" not" all" pressure" ulcers" can" be" considered" preventable" or"curable.(25)""For"example,"the"elderly"who"are"immobile"and"suffering"from"multiZ
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morbid" conditions" are" most" at" risk" from" developing" difficult" to" heal" pressure"ulcers." " In" Australian" public" hospitals" from" 2001–02," it" was" estimated" that"pressure"ulcers"occurred" in"95,695"patients"with"a"median"of"398,432"hospital"bed" days" lost" and" an" overall" cost" to" healthcare" expenditure" of" AUD285"million.(29)""Further"inZdepth"analysis"of"pressure"ulcer"cost"has"been"conducted"in" the" UK," with" the" cost" of" treating" a" Grade" 1" ulcer" being" from" GBP1,064" to"GBP10,551"for"a"Grade"4"ulcer.(30)""It"was"also"determined"that"in"the"UK,"412,000"patients"will"develop"a"new"pressure"ulcer"annually"(with"the"last"formal"costing"study"being"conducted"in"1993),"estimating"that"up"to"GBP321"million"(or"0.8%"of"UK"healthcare"expenditure)"is"spent"on"this"problem"annually.""This"figure"was"thought"to"be"a"substantial"underestimate.(30)""Another"estimate"of" this"problem"has"placed" it"as"having"a"prevalence" in"acute"care" facilities"of"between"4%"and"30%"of"patients.(24)"
"Orthopaedic" patients" immobilised" with" femoral" fractures" are" particularly"susceptible," with" an" estimated" incidence" of" 66%" and" those" in" critical" care"facilities"such"as"intensive"care"units"of"33%.(24)""Also"showing"concordance"with"Australian" and" UK" figures," the" single" cost" of" healing" a" pressure" ulcer" in" the"United" States" can" range" between" USD5–60,000.(24)" "Not" only" are" the" cost" and"duration"of"hospital" care"extended," the"presence"of" a"pressure"ulcer"places" the"patient" at" significant" risk" from" acquiring" a" nosocomial" infection." " These"infections," usually" difficult" to" treat," necessitate" further" expensive" intravenous"antibiotic" and" dressing" treatments" and" potential" surgical" intervention.(31)" "This"can"be"particularly"serious"for"elderly"patient"as"it"has"been"shown"that"pressure"ulcer"formation"is"linked"with"an"increase"in"mortality.(32)"
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Classically," a" pressure#ulcer" is" defined" as" an" area" of" local" tissues" necrosis" that"develops" when" soft" tissues" are" compressed" for" long" periods" of" time," between"bony" prominences" and" an" external" surface.(24)" " These" periods" of" prolonged"mechanical"insult"injure"the"tissues"by"causing"hypoxia"and"ischaemia,"leading"to"cell" death." " Patients" can" either" report" pain," or" pressure" ulcers" can" be" an"incidental" clinical" finding"often" reported"during" routine"nursing"duties" such"as"cleaning" and" bed" sheet" changing" in" an" incommunicable" patient.(24)" " Prolonged"pressure"on"the"tissues"leads"to"microvascular"occlusion"causing"hypoxia,"which"then" leads" to" ischaemia" causing" inflammation," increased" vascular" permeability"and"protein"accumulation"with"the" interstitium." "The" increased"oedema"further"worsens"tissue"perfusion.(24)""Cytokines"have"also"been"discovered"in"nonZhealing"pressure" ulcers," further" reducing" the" healing" process." " Studies" examining" both"acute"surgical"wounds"and"nonZhealing"pressure"ulcers"demonstrated"excessive"levels"of"activated" forms"of"matrixZdegrading"enzymes"at" the"wound"surface"of"pressure"ulcers,"further"impeding"healing.(33)"
"
Pressure)ulcers)are)graded)from)I–IV)stages:)))
Stage)1"is"nonZblanchable"erythema"of"the"skin.""The"skin"remains"intact"but"can"also"be"discoloured,"warm,"edematous"or"indurated."""
Stage)2"is"a"loss"of"skin"thickness"involving"the"epidermis,"dermis"or"both.""The"ulcer"superficially"appears"like"an"abrasion,"blister"or"shallow"crater."""
Stage) 3" involves" fullZthickness" skin" loss" involving" damage" or" necrosis" of" the"subcutaneous"tissue,"but"not"the"underlying"fascia."""
Stage)4"is"again"fullZthickness"with"extensive"tissue"destruction"involving"fascia,"muscle,"bone"and"joint.(33)""An"example"of"these"stages"can"be"seen"in"Figure"1."
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"Figure"1:"Pressure"Ulcer"Stages"from"1"to"4.(27)"
"The" best" treatment" for" a" pressure" ulcer" is" prevention." " In" addition" to" the" risk"factors" listed" above," other" risk" factors," such" as" those" occurring" naturally"with"aging"include:"decreased"epidermal"turnover,"decreased"surface"barrier"function,"sensation" (either" inherent" or" acquired" with" cerebrovascular" accidents," spinal"cord"injuries),"poor"psychological"status"(decreased"movement),"smoking," fever"and" certain" bloodZborne" illnesses" (dyscrasias," anaemia).(24," 34)" " Optimization" of"medical"coZmorbidities"can"further"reduce"the"risk"of"pressure"ulcer"formation"as"can" vigilant" nursing" care," maintaining" hydration," analgesia" and" pressure"relieving" mattresses" such" as" those" used" in" highZlevel" nursing" facilities" and"intensive"care"units.""These"mattresses"have"a"base"network"of"nonZcommunicating"air"cells" that"are"inflated"and"deflated"rhythmically"so"as"to"avoid"pressure"point"build"up,"friction"
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or"shearing.(35)""This"concept"of"repositioning" is"paramount" in"the"prevention"of"pressure" ulcer" formation." " Repositioning" by" nursing" staff" or" by" mechanical"devices" such" as" airZinflated" mattresses" must" be" performed" routinely," with" as"little" as" turning" patients" every" 4" hours" combined" with" specialised" foam"mattresses"significantly"reducing"the"incidence"of"pressure"ulcer"formation"when"compared"to"turning"patients"every"2"hours"on"standard"hospital"mattresses.(36)""Not"only"is"movement"a"key"factor"in"pressure"ulcer"prevention,"patient"support"surfaces" are" also" extremely" important." " Dynamic" systems" such" as" alternatingZpressure" air" mattresses" have" been" mentioned" above," but" static" systems" are"equally" important." " Static" mattress" designs" also" need" to" be" reZevaluated" with"mattresses"now"coming" in"a"variety"of" configurations," incorporating"air,"water,"gel"and"foam"(often"in"combination).(36)""Nutritional"optimization"of"at" risk"patients"has"also"been"demonstrated" to"help"prevent" pressure" ulcer" formation," although" the" specific" nutrients" remains"unclear.(25," 36)" " However," it" has" been" established" that" a" patient" should" be" in"positive" nitrogen" balance" to" help" prevent" pressure" ulcer" formation.(37)" " Other"helpful" factors" include" relief" of" spasticity," flexion" contracture" removal,"manual"disimpaction"to"relieve"overflow"incontinence"and"bacterial"reduction"at"sites"of"risk"(adequate"hygiene).(37)""Surgical"intervention"is"required"at"times"with"Stage"3"–"4"pressure"ulcers.""Stage"1" and"2" pressure" ulcers" are" usually" treated" conservatively." " Stage" 3" –" 4" ulcers"may" require" flap" reconstruction," although" many" may" still" be" treated"
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conservatively"due" to" severe" coZmorbidities"preventing"general" anaesthesia," or"factors" preventing" adequate" postZoperative" healing.(38Z40)" " Recent" advances" in"pressure"ulcer" care"have" advocated" the"use"of" vacuumZassisted"wound" closure"techniques," which" have" been" shown" to" be" as" effective" as" traditional" dressing"techniques." Both"methods" are" effective" for" production" of" granulation"material,"but" vacuumZassisted" therapy" also" reduces" costs" and" increases" patient"comfort.(41)""Histological"analysis"of"pressure"ulcers"treated"with"vacuumZassisted"closure" devices" have" also" demonstrated" a" decreased" inflammatory" response,"with"one"study"showing"a"decrease"of"polymorphic"neutrophils"and"lymphocytes"per" highZpower" field," and" increasing" healing" rates" with" a" decrease" in" ulcer"volume"by"51.8%"compared"to"42.1%"by"traditional"methods.(42)""Lack"of"a"coZordination"of"chemical"and"cellular"healing"has"also"been"cited"as"a"major" reason" for"delayed"healing" in"pressure"ulcers." "Angiogenesis" is"one" such"area"that"has"been"identified"as"lacking.""It"has"been"postulated"that"replacement"of" factors" (exogenously)," such" as" basic" fibroblast" growth" factor" (bFGF)," is"necessary"to"promote"healing"when"treating"pressure"ulcers.(43)""This"last"point"is"especially"relevant"to"this"study"as"the"exogenous"application"of"proZangiogenic"compounds"may"help" facilitate" faster"healing"rates,"and"reduce"patient"distress"and"discomfort"and"healthcare"expenditure.""
1.3)Burns)Pathology:)Burns" are" a" serious" problem" and" occur" at" an" alarmingly" high" rate." " Estimated"burn" injuries" in" 1991" in" the" United" States" alone" accounted" for" 5500" deaths,"51,000" acute" hospital" admissions" with" 1.25" million" total" burn" injuries"
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reported.(44)""The"main"type"of"burn"that"will"be"concentrated"on"in"regard"to"this"research" are"burns" secondary" to" thermal" injury." " Both" excessive"heat" and" cold"are" the"major"mechanisms"of" thermal"burns." "Many"of" the"victims"are" children"and" the" elderly" who" are" often" scalded" by" hot" liquids," and" also" those" whose"occupation" place" them" at" significant" risk," i.e." firemen," racing" drivers" and"petrochemical" workers.(45)" " Suffering" burns" as" a" clinical" entity" can" be" a" life"threatening" event." " Burns" that" may" involve" the" airway" can" quickly" cause"deterioration"by"occlusion"and"need"to"be"dealt"with"expediently.""Burns"affecting"large" areas" of" skin" are" also" a" medical" emergency" that" require" immediate"haemodynamic"stability"control"with"volume"resuscitation.(46)""Severe"burns"may"also" precipitate" rhabdomyolysis" (muscle" fibre" breakdown)," cardiac"dysrhythmias"and"temperature"dysregulation.(46)"The"size"and"depth"of"burns"is"extremely"important"to"the"clinician"when"assessing"a"patient"for"treatment.""The"‘rule"of"nines’"has" long"been"used" to"estimate" the" surface"area"of"an" individual"that" has" been" burned." " The" bodyZsurface" area" (BSA)" is" calculated" by" using"multiples" of" nine" assigned" to" each" specific" anatomical" region" (Figure" 2).""Children"have"a"slightly"different"calculation"required"for"estimating"BSA"due"to"the"larger"sized"head"in"proportion"to"the"body.""
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"Figure"2:"Rule"of"Nines"used"for"estimating"BodyZsurface"area"burned.(47)""
The)depth)of)a)burn)is)characterised)by)five)distinct)categories:)The"first" is"a"first)degree)or) superficial)burn." " In"a"first"degree"burn"only"the"epidermis"is"affected.""They"are"very"similar"in"appearance"to"a"sunburn"and"heal"in"a"few"days"without"significant"intervention"other"than"basic"first"aid.(46,"48)"""
Second)degree)or)partial1thickness)burns"are"further"divided"into"three"subZcategories.""""
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The"first,"superficial)partial) thickness)burns"involve"the"entire"epidermis"but"not"more" than" the"upper" third"of" the"dermis." "Rapid"reZepithelialization"occurs"due" to" the" remaining" good" blood" supply" and" remaining" functional" epidermal"cells."""
Mid1dermal) partial) thickness) burns" involve"the"epidermis"to"the" level"of" the"basement"membrane," plus" the"middle" third"of" the"dermis." "ReZepithelialization"takes"2–4"weeks"in"this"type"of"injury.(48)"""
Deep)dermal)partial)thickness)burns"involve"the"entire"epidermis"and"at"least"twoZthirds" of" the" dermis," leaving" very" few" dermal" and" epidermal" cells" to"regenerate." " Healing" is" very" slow" and" can" take" over" 4" weeks." " Surgical"debridement"of"necrotic"tissue"may"be"required"with"a"high"risk"of"scarring"and"infection.(48)"""
Full1thickness)burns"are"burns"where"destruction"of"the"entire"epidermis"and"dermis"has"occurred.""These"burns"usually"appear"leathery"and"dark;"the"skin"can"also"appear"mottled,"waxy"white"to"translucent.""The"burn"surface"itself"is"largely"painless" and" it" does" not" blanch" with" pressure.(46," 48)" "Destruction" of" the" entire"epidermis"and"dermis"leaves"no"epidermal"cells"to"repopulate." "The"wound"will"not"heal"spontaneously"and"the"area"not"closed"by"wound"retraction"will"require"skin"grafting.(48)""""Burns"exceeding"50%"of"BSA,"whether"superficial"or"deep,"are"potentially" fatal.""With" burns" affecting" more" than" 20%" of" BSA," there" is" a" significant" shift" in"intracellular" fluids" into" the" interstitial" compartment," both" at" the" burn" site" and"systemically." "These"shifts"can"be"great"enough"to"produce"hypovolaemic"shock,"once"again"reinforcing"the"importance"of"adequate"fluid"resuscitation."
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The"increase"of"local"interstitial"osmotic"pressure,"which"rises"secondarily"from"the" release" of" osmotically" active" constituents" of" dying" cells," neurogenic"mediatorZinduced" and" increased"vascular"permeability"may" induce" generalised"oedema" and" subsequent" pulmonary" oedema.(45)" " Thus," adequate" fluid" volume"and" fluid" type" (isotonic" crystalloid)" are" required" for" successful" resuscitation.""Inadequate"intravascular"fluid"volume"secondary"to"burns"results"in"circulatory"shock," also" known" as" burns# shock.(49)" " The" Parkland" formula" has" long" been"established"as"the"gold"standard"for"initial"fluid"resuscitation"for"severe"burns.(50)""The"Parkland"formula"estimates"a"24"hour"fluid"volume"replacement"of"4ml/kg"per"percentage"of"BSA"burned,"with"half"given"in"the"first"8"hours.(50)""However,"more"contemporary"thinking"advocates"the"continued"assessment"of"the"severely"burned" patient" with" realZtime" monitoring" of" urine" output," with" sufficient"resuscitation"producing"a"urine"output"of"0.5–1.0ml/hr/kg.(46)""These"efforts"aid"attempts" to" avoid" organ" system" failure" acutely" from" SIRS" (systemic"inflammatory" response" syndrome)" causing" MODS" (multiZorgan" dysfunction"syndrome)"and"the"potential"of"this"state"to"lead"to"sepsis"from"infection.(51)""Secondary" infection" is" an" important" consideration" when" dealing" with" burns."Direct"bacteraemic"spread"or"release"of"endotoxin"can"worsen"the"situation"of"a"shocked"patient,"aggravating"renal"failure"and"tissue"oxygenation"with"the"onset"of" acute" respiratory" distress" syndrome." " Prophylactic" antibiotics" are," however,"not" indicated" in" the" early" postZburn" period" and" are" best" left" until" infection"supervenes.(46)""The"burn"site"has"great"potential" for"pathogen"activity"as"serum"and"debris"provide"abundant"nutrition"for"microZorganisms." "The"burn"site"also"lacks"adequate"or"at"times,"no"blood"flow,"further"reducing"the"ability"of"cellular"
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and" humoral" immunity," as" both" phagocyte" and" lymphocyte" functions" are"impaired.(45)" " Opportunistic" infections" such" as" Pseudomonas# aeruginosa,"
Staphylococcus#aureus"and"fungi"(particularly"Candida#species)"may"be"involved.""Early"surgical"debridement"of"wounds"is"performed"with"the"goal"of"providing"a"clean" vascular" surface" on" which" wound" repair" can" take" place." " The"reconstruction"of"an"adequate"blood"supply"also"brings"about"the"reintroduction"of" immune" system" components" into" the"wound" bed," helping" to" further" reduce"infection." "Another"important"effect"of"burns"is"that"a"state"of"hypermetabolism"ensues,"with"excess"heat"loss"from"open"wounds"requiring"increased"nutritional"support.""It"is"estimated"that"when"the"BSA"approaches"40%,"the"metabolic"rate"of"the"individual"is"doubled.(45)""One"of"the"main"ways"of"treating"severe"burns"is"by"using"the"surgical"technique"of" skin" grafting." " Skin" grafting" is" not" a" new" concept," with" initial" work" by" the"Hindus"dating"back"2500"years;"however"modern"day"grafting"originated"much"later," in" 1869." " The" first" documented" skin" graft" was" actually" performed" in"Denmark"in"1870.(52,"53)""Skin"grafting"fell"out"of"favour"during"World"War"1"due"to" high" failure" rates," but" made" a" return" as" the" mainstay" of" treatment" during"World" War" 2," when" treatment" of" numerous" burned" aircrew" allowed" new"techniques" to" emerge.(52," 54)" " The" two" main" types" of" grafts" used" in" burns"treatments" are" split" thickness"or" full" thickness" grafts." "Both"of" these" grafts" are"autologous" in" nature." " Split" thickness" skin" grafts" contain" the" epidermis" and" a"varying"thickness"of"the"epidermis.""Initially,"blood"and"nutrients"are"supplied"to"the" graft" by" osmosis,"with" the" thinner" the" graft" the" easier" the" diffusion." " Split"
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thickness"skin"grafts"are"indicated"for"large"areas,"cavities"and"mucosal"defects.""Graft"acceptance"follows"four"main"phases"(Table"3).(53)"Table"3:"Skin"graft"acceptance"stages.(53)""
"It"must"noted" that" the"mechanism"of"angiogenesis"during" the" revascularisation"process" is" unknown." " Recent" advances" in" spray.on" skin" technology" both" in"Australia" and" abroad" advocate" that" the" technology" can" treat" severe" second"degree"burns,"by"simply"spraying"on"new"basalZstem"skin"cells.(55)""This"sprayZon"skin" technology" involves" the" surgeon" taking" a" small" sample" of" cells" from" a"burned" patient," creating" a" suspension" of" the" cells" and" then" spraying" them"directly"onto"the"patient’s"skin.""This"sprayZon"technology"endeavours"to"achieve"a"result"at"least"comparable"to"traditional"skinZgrafting.(55)""However,"at"this"point"in" time," this" technology" lacks"multiZcentre," randomised" controlled" trials" and" is"not"supported"by"major"burn"units"nationally"or"internationally.(56)""The"exact"circumstances"that"would"be"favourable"for"sprayZon"technology"to"be"successful"are"not"certain"either." "Other"studies" involving"reconstructed"human"
The knife is preferred for areas that are difficult to access or have
irregular borders. Dermatomes are used for large areas of consis-
tent contour and thickness (e.g. thigh or back) and may be driv-
en by air or electricity.2,3,4 (See Figure 1)
Physiology of Graft Take
Graft take occurs in four stages (see Table 1 below).
Table 1. Stages in Graft Take
Stage Event
Imbibition Day 0-3. The graft receives nutrients from the
plasma through direct contact
Revascularization Day 3-7. Exact mechanism is unknown. Graft and
donor site regenerate or generate new blood
vessels, which anastomose and allow blood flow
to begin.
Regeneration Dermal appendages and sweat glands regenerate.
Reinnervation begins and the graft takes on
recipient site sweating pattern.
Reinnervation Graft takes on nerve pattern of recipient site.
Although STSG are reinnervated faster, FTSG
have a better final result.
Applications/I dications
Wounds that have skin loss close naturally by two main mech-
anisms: epithelial migration and wound contraction.
Contraction is a consequence of gr nulation tissue formation
and myofibroblasts, which allow the wound edges to tighten and
shrink together. This creates an area of tight skin called a con-
tracture, which may be nde rable in ar as that are highly visi-
ble or require mobility, such as the skin over joints. Further,
wounds closed through epithelial migration occur from the
wound edges, but lack the anchors, called rete pegs, that secure
epidermis and dermis so the tissue is easily avulsed.3 When these
natural processes are insufficient, the surgeon has the option of
a skin graft or flap.
Basic Surgical Procedure
Grafting takes place in several stages, often through multiple
operations. The exact plan of action depends on the sites chosen,
wound type, cov r ge ne ded, infection, patie t’s medical condi-
tion, and other factors. Only when the plan is coordinated will
the operations begin. The following is an example of skin graft
harvest and placement, as performed by the authors while at the
Ross Tilley Burn Centre at Sunnybrook Hospital in Toronto,
Ontario. Many variations of this procedure exist.
To prepare the donor site, the surgeon chooses an area based
on availability of healthy skin, visibility of a scar, patient prefer-
ence, etc. If the recipient site is above the clavicles, then the ideal
donor site is also from the “blush zones” above the clavicles. This
provides a closer colour and texture match for a better cosmetic
result.3,4
Operative sites are marked, prepared, and draped. The donor
site is injected with a tumescent solution containing saline to firm
and even out the skin and epinephrine to locally vasoconstrict and
decrease bleeding. If a dermatome is used, mineral oil is applied
and the dermatome is used to harvest the skin. Once obtained,
the graft is kept moist and sterile.2 A stiff plastic backing may be
used to spread out the graft and to mesh if necessary.
Once the grafts have been obtained, the recipient site is pre-
pared as needed – for example, temporary skin dressings are
removed and dead or unhealthy tissue debrided. Grafts are
applied on the tissue bed and may be attached using staples or
surgical glue.
Grafts may be meshed (See Figures 2 and 3). This maximizes
the area covered by a graft and minimizes the amount of donor
site needed. It allows the graft to better achieve the contour of the
recipient site, making for a better graft take and permitting fluid
drainage, thereby decreasing the risk of a hematoma or seroma.
However, themarks of meshing will remain, making it a technique
to be avoided on areas like the face and arms, where a more desir-
able cosmetic effect can be achieved by sheet graft. Another char-
acteristic of meshing is that the graft is more likely to contract; this
effect may help shrink the wound, but is best avoided over joint
areas.4
Skin Grafts
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Figure 2. Meshing device and graft.
Figure 3. Meshed graft.
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skin"engineered"from"autologous"keratinocytes,"fibroblasts"and"sterilized"donor"allodermis"was"seen"to"stimulate"angiogenesis"in"5–7"days,"but"only"when"placed"on"wellZvascularised"wound"beds"in"nude"mice.(57)""When"the"grafts"were"placed"on" more" difficult" wound" beds," many" were" lost" with" potential" delayed"vascularisation"being"cited"as"a"contributing"failure"factor.(57)""Other"factors"such"as"graft"hypoxia"and"site"of"endothelial"cell"addition"have"also"been"identified"as"potential"approaches"to"improve"graft"angiogenesis.(58)""The"use"of"a"topical"proZangiogenic"agent"may"be"of"profound"use" in"helping"to"vascularise"graft"beds"earlier"and"more"reliably,"ensuring"enhanced"survivability"and"decreasing"the"risk"of"infection"that"can"compromise"early"graft"subsistence.""
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1.4)Basic)Wound)Healing)Concepts"Normal" cutaneous" wound" healing" is" a" complex," delicate" and" multiZstepped"process.""There"are"over"100"factors"required"to"successfully"heal"a"wound.""The"first" concept" in" considering" wound" healing" from" a" clinical" perspective" is" the"analysis" of" the" vascular" response," the" cellular" response," growth" factor"involvement"and"both"systemic"and"local"factors"affecting"wound"healing.(16,"17,"59,"
60)" "It"would" therefore" be" appropriate" to" commence"with" a" brief" description" of"normal"cutaneous"(skin)"anatomy.""The"skin"consists"of"two"major"components:"the" epidermis" and" the" dermis" (Figure" 3).(61)" " The" epidermis" is" further" subZdivided" into" five" distinct" layers" from" superficial" to" deep:" Stratum" corneum,"Stratum" lucidum," Stratum" granulosum," Stratum" spinosum" and" Stratum" basale"(Figure"4).(62)""
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"Figure"3:"Structure"of"the"skin"and"subcutaneous"tissue.(61)""
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"Figure"4:"Photomicrograph"showing"the"layers"of"the"skin.(62)""The"surface"of" the"skin" (epidermis)" consists"of"keratinized"stratified"squamous"epithelium" and" contains" sweat" and" sebaceous" glands," hair" and" nails.(61)" " The"deeper"layer"(dermis)"consists"mainly"of"bundles"of"collagen"fibres"together"with"elastic" tissue," blood" vessels," lymphatics" and" nerve" fibres.(61)" The" skin" has" an"approximate"surface"area"of"1.5–2.0"square"metres"and"weighs"approximately"4–5kg" (approximately" 7%" of" an" individual’s" body" weight).(62)" " Ten" square"millimetres" of" skin" contains" approximately" 70cm" of" blood" vessels," 55cm" of"
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nerves,"100"sweat"glands,"15"oil"glands,"230"sensory"receptors"and"half"a"million"cells"constantly"dying"and"being"replaced.(62)"
"The"skin"performs"several"vital"functions,"the"first"being"that"of"protection.""The"skin" forms" a" mechanical" and" biological" barrier" by" the" use" of" waterproofing"glycolipids" preventing" diffusion" into" and" from" the" body" of" various" substances"and" providing" immunological" protection" by" the" presence" of" Langerhans’" cells"and"dermal"macrophages.""Temperature"regulation"is"another"important"function"of" the" skin,"mainly" via" the"mechanisms" of" sweat" and" blood" vessel" constriction"and"dilatation"(convective"heat"loss).(62)" "As"mentioned"above,"the"skin"contains"numerous"physical" sensors" (cutaneous"nerves" cells" known"as" exteroreceptors)"and" can" detect" situations" such" as" pressure," pain" and" temperature" change" and"allow"the"organism"to"navigate"and"interact"with"the"external"environment"and"avoid"noxious" stimuli.(62)""The" skin" also"hosts" several" other" important" chemical"and" physical" factors" such" as" Vitamin" D" conversion," potential" blood" reservoir"(holding" approximately" 5%" of" circulating" volume)" and" excreting" unwanted"chemicals"such"as"nitrogenZcontaining"waste.(62)""Collectively,"the"structures"that"form"an"individual’s"skin"is"known"as"the"Integumentary"system.""Insults" causing"wounds" to" the" skin" can" arise" from"a"multitude"of" sources"with"four"main"types"commonly"being"accepted.""The"first,"lacerations,"arise"when"the"tissues"are"cut"or"torn.""This"type"of"wound"can"result"from"a"traumatic"accident"or"can"be" iatrogenic"(wounds"created" intentionally"by" the"surgeon"to"achieve"a"therapeutic"goal).""It"is"not"usual"for"these"wounds"to"result"in"a"significant"tissue"deficit"as"they"heal"by"primary"intention.""The"second,"abrasions,"occur"when"a"
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superficial" layer" of" tissue" is" removed," commonly" seen" in" superficial" partialZthickness"burns.""Contusions"are"the"third"type"of"wound"and"usually"occur"after"forceful" blunt" trauma" to" the" skin," with" the" most" superficial" layer" remaining"intact." " However," these" wounds" may" need" to" be" opened" up" by" an" incision" to"relieve" pressure" that" can" accumulate" below," with" this" pressure" compromising"effective" blood" supply" to" the" damaged" tissues." " The" fourth" type" of" wound,"
avulsion,"is"when"a"section"of"tissue"has"been"removed.""The"ability"to"repair"this"defect"will"be"determined"by"the"nature"of"the"wound." "For"example"the"wound"may"allow"for"repair"and"closure"of"the"defect"by"use"of"a"flap,"a"skin"graft"or"it"may"be"left"to"heal"by"secondary"intention.(63,"64)""Primary" (first)" intention" healing" is" the" least" complicated" and" most" desired"manner"of"healing." "An"example"of"primary"intention"healing"would"be"that"of"a"surgical" incision" closed" with" varying" suturing" techniques." " The" wound" causes"minimal"interference"to"the"tissue"architecture"by"limited"epidermal"and"dermal"cell"death"and"disturbance"of" the"epithelial"basement"membrane.(60)""The"deficit"left"is"minimal"and"is"immediately"filled"with"clotted"blood"containing"fibrin"and"platelets." "Within" 24" hours" neutrophils" appear" in" the"wound" and" by" 48" hours"epithelial" cells" move" from" the" wound" edges" depositing" basement" membrane"components." "These"edges" then" fuse"under" the"surface"of" the"wound" forming"a"continuous"thin"epithelial"layer"(Figure"5).(60)""
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"Figure"5:"Healing"by"first"(primary)"and"secondary"intention.(60,"65)""By"72"hours"after"the"initial"insult,"the"neutrophils"have"largely"been"replaced"by"macrophages" and" granulation" tissue" progressively" invades" the" deficit.""Granulation" tissue"contains"numerous"new"blood"vessels"being" initially" formed"by" the" secretion" of" VEGF" (vascular" endothelial" growth" factor)." " VEGF" is" also"responsible" for" the" increase" in" vascular" permeability" seen" in" granulation"tissue.(60)" " This" increase" in" permeability" is" vital" for" the" exudation" of" plasma"proteins,"especially"fibrinogen"and"plasma"fibronectin"in"the"ECM"(extraZcellular"matrix)"forming"a"provisional"stroma"for"fibroblast"and"endothelial"growth.(60)"
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Fibroblast"migration,"proliferation"and"function"are"cornerstones"to"healing"the"site" of" injury." " Fibroblast" manipulation" is" also" a" highly" desired" method" of"accelerating"wound"healing.""There"are"various"growth"factors"that"contribute"to"fibroblast"effectiveness"such"as"TGFZβ"(transforming"growth" factor"beta),"PDGF"(plateletZderived"growth"factor),"EGF"(epidermal"growth"factor),"FGF"(fibroblast"growth" factor)," ILZ1" (InterleukinZ1)" and"TNF" (tumor"necrosis" factor)." "Of" these"factors," TGFZβ" is" one" of" the" most" important," being" foremost" produced" by"granulation" tissue" and" increases" fibroblast" migration," proliferation" and"increased"synthesis"of"collagen"and"fibronectin.""It"also"reduces"the"degradation"of"the"ECM"by"metalloproteinases.""TGFZβ"is"also"chemotactic"for"monocytes"and"has"been"shown"to"be"proZangiogenic" in" in#vivo" studies,"probably"by" increasing"macrophage"influx.(60)""Collagen"synthesis"by"fibroblasts"begins"usually"within"3–5"days"of"the"healing"process,"continuing"for"several"weeks.""Collagen" accumulation" depends" on" synthesis" but" also" on" degradation" and"conversion" into" scar" tissue" comprising" dense" collagen," sparse" remaining"fibroblasts,"elastic" tissue"and"ECM"remnants." "At" this"point,"vascular"regression"occurs" leaving"an"avascular"scar.(60)""An"example"of"the"cytokine"overlap"can"be"seen"in"Figure"6"overleaf.""
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"Figure"6:"Cytokine"overlap"occurring"during"acute"and"chronic"wound"healing.(66)""Manipulation"of"fibroblast"activity"could"also"potentially"heal"wounds"quicker"by"a"twoZfold"method"–"firstly"by"increasing"angiogenesis"via"selected"growth"factor"release"at"the"site"of"injury"and"prolonging"it,"and"secondly"by"possibly"increasing"the"yield"of"collagen"produced"by"active"fibroblasts.""Collagen"fibres"present"at"the"margins"of"the"wound"but"do"not"span"the"entire"wound,"with"the"epidermal"layer"continuing"to"thicken"throughout"this"process.""By"Day"5,"the"space"is"filled"with"granulation"tissue"and"neovascularization"(neoZangiogenesis)"is"at"maximal"levels.(17,"60)""It"is"also"prudent"to"note"at"this"juncture"that"studies"reveal"that"Day"5"is"also"the"stage"of"maximal"neoZangiogenesis"for"wounds,"using"mouse"models.(67)""By"this"stage"collagen"begins"to"span"the"wound"and"the"epidermis"recovers"normal"thickness." "During"the"second"week"there"is"
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continued" accumulation" of" fibroblasts" and" collagen" along" with" wound"contracture.""Vascular"channels"also"decrease"at"this"stage.""The"wound"continues"to"gain"strength"over"the"next"month"2–3"months"(Figure"7).(59,"60)""Simplistically,"these"phases"of"wound"healing"can"be"broken"down"into"haemostasis"(<4"hours),"inflammation"(<24–48"hours)"and"proliferation"(48"hours–5"days).(17,"68,"69)""
"Figure"7:"Phases"and"Duration"of"Wound"Healing.(60)"
Wound" healing" is" also" augmented" by" several" important" growth" factors" and"cytokines," as" mentioned" previously," also" including" ANG" (angiopoietin).(60)" " In"several" studies," it" has" also" been" found" that" external" augmentation" of" these"numerous" cytokines" and" growth" factors" can" accelerate" wound" healing" under"certain" conditions," with" bFGF" (basic" fibroblast" growth" factor)" having" the"potential"to"be"manipulated"in"this"way.(70,"71)"
Healing"by"secondary"intention"is"a"much"slower"process"and"occurs"in"avulsion"and" abrasion" type" wounds" where" there" is" a" much" larger" loss" of" tissue." " The"
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reparative" process" is" more" complex" and" preZinsult" architecture" cannot" be"restored." " The" defect" left" from" secondary" healing" usually" consists" of" more"necrotic"debris"and"exudate.(60)""These"wounds"are"thus"more"prone"to"infection"and" have" a" larger" inflammatory" response" and" require" larger" amounts" of"granulation" tissue." " The"healing" response" is" similar" to" that" of" primary"healing;"however" a" phenomenon" of" wound" contraction" occurs" more" prominently" in"secondary" intention" healing." " Myofibroblasts" predominate" in" the" wound" and"contract" at" the"wound"edges" to"decrease" the"gap"between" the"dermal" edges"of"the"wound.""Scar"formation"is"inevitable"with"this"type"of"healing"(Figure"5).(60)"
1.5)Angiogenesis)and)Wound)Healing)in)Diabetics:)Diabetes" impairs" wound" healing" through" a" number" of" mechanisms" such" as"reducing" growth" factor" production," the" angiogenic" response," macrophage"production," collagen" accumulation," epidermal" barrier" function," quantity" of"granulation"tissue,"and"keratinocyte"and"fibroblast"migration,"to"name"a"few.(72)""A"common"issue"with"diabetic"wounds"is"that"healing"is"decreased,"mainly"due"to"reduced"angiogenesis,"both"in"rate"and"quantity.""Angiogenesis"is"the"critical"step"required" for" the" delivery" of" cytokines" and" raw" materials" needed" for" effective"wound"healing"to"occur.""Angiogenesis"has"been"considered"to"be"dependent"on"the" number" of" branching" blood" vessels" and" network" of" adjacent" vessels.""However," recent" studies" have" shown" that" angiogenesis" can" occur" after"systematic" recruitment" of" endothelial" progenitor" cells" (EPCs).(60," 73Z76)""Angiogenesis"is"a"crucial"component"of"wound"healing"and"worldwide"there"is"a"substantial" interest" in" increasing" rates" of" angiogenesis" and" conversely" for"inhibiting"it"(antiZcancer"treatments).(60)""Angiogenesis"occurs"in"two"main"ways:"
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1. Angiogenesis" during" embryological" development" from" endothelial"precursor"cells,"often"called"vasculogenesis,"and;"2. Angiogenesis"from"preZexisting"vessels.(60)""The" formation" of" both" the" haematopoietic" systems" and" vascular" networks" are"closely" linked." " During" embryonic" development," these" systems" both" originate"from" the" haemoangioblast.(60," 77," 78)" " The" haemoangioblast" gives" rise" to" both"haematopoietic" stem" cells" and" angioblasts," which" then" form" blood" vessels.""Angioblasts"migrate" to" peripheral" sites"where" they" can" further" differentiate" to"form"arteries,"veins"and"lymphatics." "Classically,"this"is"in"the"context"of"healing"in" already" established" tissues," but" it" must" be" remembered" that" angiogenesis"occurs"in"an"originally"avascular"environment,"the"embryo.(79)"
"Initially," the" embryo" survives" on" diffusion" alone" and" the" production" of" an"organized"vascular"network"follows"as"an"ordered"and"time"sequential"evolution.""When" angiogenesis" is" taking" place" in" the" embryo," angioblast" cells" migrate" to"discrete"locations,"differentiate"in#situ"and"construct"endothelial"cords,"forming"a"plexus" of" endocardial" tubes.(79)" " An" example" of" this" can" be" seen" in" Figure" 8"overleaf." " The" process" then" continues" to" sprout" vessels" from" both" endZon" and"sideZon," differentiating" into" arteries," capillaries" and" or" veins." " Pericytes" then"surround"the"primitive"network"and"give"rise"to"vascular"myogenesis,"eventually"leading"to"viscoelastic"and"vasomotor"properties.(79)""
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"Figure"8:"Angioblasts"in"the"embryo"assemble"a"primitive"network"that"expand"and"remodel.(79)""Angiogenesis" can" be" viewed" on" a" molecular" basis" as" a" dependent" stepZwise"process." " The" initial" vasodilation" of" vessels" is" followed" by" increases" in"permeability" and" degradation" of" the" surrounding" matrix." " This" allows" the"activated"endothelial"cells"to"proliferate"and"form"lumens,"sprouting"to"form"new"vessels.(79)" " These" sprouted" vessels" then" differentiate" and" adapt" to" local"requirements,"supported"by"a"scaffolding"of"differentiated"periZendothelial"cells"and"matrix." " These" then" remodel" to" form" the" required" vascular" plexus.(79)" "An"example"of"this"can"be"seen"in"Figure"9"overleaf.""
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Fig. 1. Endothelial precursors (angioblasts) in the embryo assemble in a primitive network (vasculogenesis), that expands and remodels (angiogenesis).
Smooth muscle cells cover endothelial cells during vascular myogenesis, and stabilize vessels during arteriogenesis. CL, collagen; EL, elastin; Fib, fibrillin.
With permission from Ref. [4].
outside of the embryo proper, on the yolk sac, as focal the center constitute hematopoietic precursors. The molec-
aggregations of mesenchymal cells, known as blood is- ular signals determining the fate of the hemangioblast are
lands, form within the mesoderm adjacent to the ex- not fully elucidated. However, several genes have been
traembyronic endoderm. While the earliest studies sug- identified that may play a role in this early event [7]. These
gested that the embryo proper becomes vascularized from include Ets-1 [8], Hex [9], Vezf [10], Hox [11,12],
branching and growth of extraembyronic blood vessels members of the GATA-family, basic helix-loop-helix
which in turn are derived from fusion and channeling of (bHLH) factors [13,14], an the Id-proteins [15]. The
blood islands, intraembryonic origins of a vascular net- earliest markers common to endothelial and hematopoietic
work were recognized as early as 1900 when it was precursors so far identified are CD31, CD34 and the
d ter ined that cells from isolated embryos were able to receptor tyrosine kinase type-2 of vascular endothelial cell
give rise to blood vessels. It was at this time that the term growth factor (VEGFR-2 or KDR/Flk1) [16]. Inactivation
angioblast, referring to the cells from which all endothelial of the VEGFR-2 gene in mice results in embryonic
cells aris , was described. It was al o during this early lethality, with lack of development of both hematopoi tic
period that the presence of the hemangioblast — a and endothelial cell lineages, supporting the critical impor-
common precursor for both endothelial cell and hemato- tance of this receptor at that developmental stage [17],
poietic cell — was first postulated (Fig. 2). Notably, it was although not defining the steps regulating differentiation
almost 100 years later that the presence of the hemangio- into endothelial versus hematopoietic cell.
blast was confirmed [5]. Differentiation of pluripotent As the yolk sac vasculature begins to form |7.5 days
embryonic precursor cells into hemangioblastic cells is post coitum (dpc) in the mouse, angioblasts that have
induced to at least some extent by fibroblast growth factor migrated to the paraxial mesoderm assemble into aggre-
(FGF) via protein kinase C signaling [6]. Hemangioblasts gates, proliferate and subsequently differentiate to form a
undergo their first critical steps of differentiation within the plexus with endocardial tubes, leading to formation of the
blood islands. Cells at the perimeter of the blood islands dorsal aortae, cardinal veins and the embryonic stems of
give rise to precursors for endothelial cells, while those at yolk sac arteries and veins (Fig. 3). Vasculogenesis was
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"Figure"9:"Brief"overview"of"angiogenesis"(sprouting)"in"the"adult.(79)""As" mentioned" above," angiogenesis" from" EPCs" occurs" because" of" the" close"relationship"between"the"vascular"and"haematopoietic"systems." "These"systems"share" a" common" precursor," the" haemoangioblast," which" can" generate" both"haematopoietic" stem" cells" and" angioblasts" capable" of" proliferation," migration"and" differentiation" into" endothelial" cells" giving" rise" to" arteries," veins" and"lymphatics.(60," 79)" " Angioblasts" are" also" capable" of" generating" pericytes" and"smooth"muscle"cells"of"the"vessel"wall"(periendothelial"cells).(60,"80,"81)""AngioblastZlike"cells"have"been"discovered"in"adult"bone"marrow"and"have"been"shown"to"be"recruited"into"tissues"to"initiate"angiogenesis.(60,"79,"82)""An"example"of"this"in"both"the"adult"and"embryo"can"be"seen"overleaf"in"Figure"10."
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Fig. 3. Pathological vascular growth in the adult may occur via vasculogenesis (angioblast mobilization), angiogenesis (sprouting) or arteriogenesis
(collateral growth). With permission from Ref. [4].
not only impact on angiogenic therapies, but also on in tumors appears to be particularly complex, possibly
treatment of a variety of hematologic disorders. because the malignant cells derail the process via chaotic
expression of angiogenic factors. As each of these steps is
better elucidated, greater potential for therapeutic interven-
tion will be forthcoming.
3. Angiogenesis
3.1. Existing vessels dilate, vascular permeability
The molecular basis of angiogenesis is most easily increases and extracellular matrix is degraded
characterized by viewing the process as a step-wise
progression (Figs. 3 and 4). Th initial vasodilation of Largely in response to nitric oxide (NO), vasodilation is
existing vessels is accompanied by increases in permeabili- one of the earliest steps in angiogenesis. VEGF, transcrip-
ty and degradation of surrounding matrix, which allows tionally upregulated in part by NO [29], mediates an
activated and proliferating endothelial cells to migrate and increase in vascular permeability, accomplished through
form lumens. The endothelial cells of these ‘sprouting’ redistribution of intercellular adhesion molecules, includ-
new vessels differentiate to accommodate local require- ing platelet endothelial cell adhesion molecule (PECAM)-1
ments, supported by a surrounding network of similarly and vascular endothelial (VE)-cadherin, and alterations in
differentiated peri-endothelial cells and matrix, all of cell membrane structure via induction of a series of kinases
which mature through remodelling into a complex vascular [30,31]. Extravasation of plasma proteins follows, similar-
network, ultimately lined by endothelial cells that have ly induced by VEGF, these being required for creating a
acquired critical survival factors, optimized to function temporary support structure, as activated endothelial cells
under a variety of onditions. Our understanding of the subsequently migrate. Not surprising, excessive vascular
cellular and molecular mechanisms in angiogenesis, in permeability could result in pathological outcomes, such as
cancer and other diseases is still limited. Capillary growth intracranial hypertension or circulatory collapse. Conse-
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"Figure"10:"Endothelial"Progenitor"Cells"(EPCs)"recruitment"and"importance"in"new"blood"vessel"formation"in"both"the"adult"and"embryo.(60,"79)""The" exact" mechanism" of" chemotaxis" involved" in" EPC" signalling" still" remains"unknown.(60,"83,"84)""Circulating"EPCs"in"adults"express"markers"of"haematopoietic"stem"cells"as"well"as"markers"such"as"VEGF,"EZselectin"and"TieZ2"receptor.""EPCs"participate" in" replacement" of" lost" endothelial" cells" in" vascular" implants,"ischaemic"organs,"wounds"and"tumours.(60)""Angiogenesis" in"preZexisting"vessels"occurs"after"direct"response"to"vasodilation"and"vessel"permeability"secondary"to"nitric"oxide"and"VEGF.""Proteolytic"degradation"of"the"basement"membrane"then"occurs"by"metalloproteinases"allowing"for"migration"of"endothelial"cells"toward"the"angiogenic"stimulus.(60)""Proliferation"of"endothelial"cells"behind" the" leading"migrating" cells" then" occurs;" the" cells" then" mature" and" remodel" into" capillary"
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Fig. 2. A common origin for the two types of blood-vessel cell. Endothelial and smooth muscle cells arise from separate types of precursor. Endothelial
cells arise from precursors called angioblasts or hemangioblasts in the embryo, or from circulating endothelial progenitors in the adult. Angioblasts give
rise to arterial and venous lineages. Smooth muscle cells and pericytes, by contrast, can form from a variety of progenitors. These include mesenchymal
cells, neural crest cells, and progenitors in the epicardium in the embryo. Progenitors in the bone marrow and its stroma, and mesenchymal myofibroblasts
also give rise to smooth muscle cells. A new common vascular progenitor cell that gives rise to both types of blood-vessel cell has been recently identified.
Vascular endothelial growth factor (VEGF) promotes the development of endothelial cells from this precursor. TGF-b1 has been involved in differentiation
of mesenchymal cells to progenitors, that express the receptor for PDGF-BB. The latter stimulates their development into smooth muscle cells and
pericytes and is responsible for their recruitment around nascent vessels. Adapted from Ref. [114].
originally believed to be restricted to embryonic develop- natally [18,22,23]. Angioblast differentiation may be pro-
ment. However, it has been established that angioblasts not moted by VEGF, VEGFR2 and basic fibroblast growth
only migrate intraembryonically, but may circulate post- factor (bFGF) [24–27], while VEGF receptor-1 (VEGFR-
natally, and may be recruited for in situ vessel growth 1; Flt1) has been determined to suppress hemangioblast
[18–20] (Fig. 4). Unlike shed cells, circulating CD34/ commitment [28]. The findings that endothelial cells still
VEGFR-2/AC133-positive marrow-derived angioblasts in develop in mice engineered to lack VEGF but do not
the adult have a high proliferation rate [21]. How angiob- develop any longer in the absence of VEGFR-2, suggests
lasts ‘know’ where and when to initiate vasculogenesis is that there are additional molecules, binding to VEGFR-2,
largely a mystery, although a variety of growth factors and that determine endothelial cell fate. Although vas-
receptors, including vascular endothelial growth factor culogenesis is closely linked to hematopoiesis, precursors
(VEGF), granulocyte monocyte-colony stimulating factor of definitive hematopoietic cells arise only from the dorsal
(GM-CSF) and other cytokines have been implicated, as aorta, and subsequently populate the liver, spleen and bone
they have been shown to be able to recruit bone-marrow marrow. A basic understanding of the molecular mecha-
derived angioblasts to sites of neovascularization post- nisms that separate hematopoiesis from vasculogenesis will
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tubes" and" further" recruitment"of"periZendothelial" cells" occurs" to"help" form" the"mature" blood" vessel.(60," 79)" " Figure" 11" briefly" summarizes" the" numerous"stimulators" and" inhibitors" involved" in" adult" angiogenesis." " Incidentally," FGFZ7"deficiency"has"also"been"cited"as"a"major"contributing"factor"to"delayed"healing"in"diabetic"wounds.(85)""
"Figure"11:"Brief"summary"of"the"numerous"stimulators"and"inhibitors"involved"in"adult"angiogenesis.(79)""A"critical"step"impaired"in"the"healing"process"of"diabetic"wounds"is"the"reduced"ability" to" form" new" blood" vessels" within" these" wounds.(72)" "The" most" notable"vascular"problems"are"associated"with"diabetics"in"regards"to"macroZ"and"microZangiopathy" (macroZ" and" microZvascular" disease" respectively)." " In" diabetic"macrovascular" disease," the" most" distinguishing" feature" is" that" of" advanced"atherosclerosis" of" the" largeZ" and" mediumZsized" arteries.(8)" " Advanced"atherosclerosis"causes"a"number"of"complications;"however"the"most"significant"is" of" a" decreased" supply" of" blood" (ischaemia)" to" the" extremities." " The" reduced"
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Fig. 4. VEGF initiates assembly of endothelial cells (EC), PDGF-BB recruits pericytes (PC) and smooth muscle cells (SMC), whereas angiopoietin-1
(Ang1) and TGF-b1 stabilize the nascent vessel. Angiopoietin-2 (Ang2) destabilizes the vessel, resulting in angiogenesis in the presence of angiogenic
stimuli, or in vessel regression in the absence of endothelial survival factors. With permission from Ref. [4].
quently, permeability changes must be tightly regulated. inhibitors of MMPs include circulating protease inhibitors,
Angiopoietin-1 (Ang1), a ligand for the endothelial re- such as tissue-localized inhibitors of metalloproteinases
ceptor Tie2, is a natural anti-permeability factor, that (TIMPs) [35]. It is at least partly through the secretion of
provides protection and a balance against excessive plasma MMP-2, MMP-3 and MMP-9, and suppression of TIMP-2
leakage [32]. that Ang1 induces sprouting [36]. Similarly, MMPs 3, 7
Endothelial sprouting is further enhanced by another and 9 have been shown to induce angiogenesis in neonatal
member of the angiopoietin family, Ang2, an inhibitor of bones and tumors [37]. MMPs do not uniformly enhance
Tie2 signalling and a natural antagonist of Ang1. Ang2, angiogenesis, however. Temporal and spatial factors likely
appearing at angiogenic and vascular remodelling sites, is dictate their function. For example, MMPs 1 and 3 may
involved in detaching smooth muscle cells and loosening also inhibit tumor angiogenesis by interfering with binding
underlying matrix, thereby allowing endothelial cells to of MMP-2 to integrins [38], while MMPs 7 and 9 generate
migrate as inter-endothelial cell contacts are relieved angiostatin from circulating plasminogen, thereby inhib-
[31,33]. Degradation of extracellular matrix involves an iting endothelial cell proliferation [39]. Interactions with
array of proteinases which not only provides ‘room’ for the other proteins also alter their roles in angiogenesis.
migrating endothelial cells, but also results in the liberation Thrombospondin-1 (TSP-1) is believed to be nti-an-
of growth factors, including bFGF, VEGF and insulin-like giogenic by preventing activation of MMP-2 and MMP-9
growth factor-1 (IGF-1), which otherwise remain seques- [40]. Optimal angiogenic function of MMP-9 may require
tered within the matrix. Ov r 20 matrix metallopro einases cell-surface localization with t e hyaluronan receptor
(MMPs) have been described and implicated in angio- CD44 and TGF-beta [41]. Other proteinases have also been
genesis, tumorigenesis and cell proliferation (reviewed in implicated in matrix degradation enabling endothelial cell
Ref. [34]). In addition, they can expose cryptic adhesion migration. Notably, urokinase-type plasminogen activator
sites, hidden in non-proteolyzed matrix components. As (u-PA) is essential for revascularization of myocardial
the name implies, MMPs play a central role in degrading infarcts [42,43], while antagonists of u-PA or its interaction
extracellular membranes and basement embrane struc- with the u-PA have in vivo anti-angiogenic therapeutic
tures, allowing endothelial migration to occur. Natural potential [43,44]. A fine-tuned balance between proteinases
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blood"supply"causes"a"number"of"issues,"the"paramount"being"an"increase"in"the"rate"of"gangrene,"which"develops"at"a"rate"almost"100"times" faster" than"that"of"nonZdiabetics." " Coupled" with" a" decrease" in" blood" supply" and" immuneZsystem"functioning,"infections"are"also"more"prevalent"in"diabetics.(8)"""
"With"advancing"diabetes,"diabetic"neuropathy" intervenes,"affecting"sensation"of"the" lower" limbs" and" preventing" sufferers" from" consciously" acknowledging"repeated" trauma" to" healing" wound" sites." " Also" nonZenzymatic" glycosylation"predisposes" leg" ligaments" to" stiffness," causing" the" foot" to" undergo" abnormal"motion"with"the"emergence"of"new"and"smaller"pressure"points,"compromising"blood"flow"further.(86)""The"end"result"is"neuropathic"arthropathy,"a"Charcot"foot.""Due"to"this"combination"of"pathologies"caused"by"diabetes,"ulcer"formation"and"subsequent"infection"are"major"issues"for"the"diabetic.""As"mentioned"previously,"amputation" is" a" common" endZpoint" for" many" sufferers" of" advanced" diabetic"complications" of" the" lower" limb." " An" overview" of" how" diabetes" affects"wound"healing"can"be"seen"in"Figure"12"overleaf.""
46""
"Figure"12:"Impact"of"diabetes"on"normal"wound"healing"and"angiogenesis"(neovasculogenesis).(87)"
)
1.6)Topically)Applied)Pro1Angiogenic)Compounds:)It"has"been"shown"in"several"studies"that"diabetes"impairs"the"ability"for"EPCs"to"migrate" to" the" site" of" insult" and" partake" in" angiogenesis," thus" significantly"impairing"wound"healing.(88Z90)" "As"angiogenesis" is" vital" to"wound"healing,"new"approaches" must" be" explored" to" increase" its" rate." " For" example," several"compounds"applied"topically"have"already"been"shown"to"improve"angiogenesis"in"wounds.""Topically"applied"VEGF"has"been"shown"to"increase"diabetic"wound"healing" rates" through" increased" angiogenesis" and" recruiting" of" EPCs.(71," 82)""Likewise,"nicotinic"acid"has"also"been"shown"to"increase"the"rate"of"angiogenesis"in"diabetic"mice,"thus"accelerating"healing"rates.(91Z93)"PDGF"and"FGF"have"similar"action.(94)" " The" several" compounds" just" mentioned" suggest" the" potential" for" a"
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combined,"polyZpharmaceutical"approach"to"wound"healing.(91Z94)""It"is"proposed"that"accelerated"wound"healing"will"significantly"decrease"the"rate"of" ulcer" formation" and" subsequent" infection" that" commonly" arises," especially"with"diabetes.""If"this"is"possible,"it"will"significantly"improve"morbidity"in"a"vast"array" of" patients," not" only" limited" to" diabetics." " Additional" patients" may" also"include"trauma"and"burns"patients,"the"elderly,"the"malnourished"and"those"with"underlying" genetic" deficiencies" affecting" wound" healing." " Proposed" outcomes"would"potentially"reduce" the"need" for"operative"procedures"such"as" traditional"wound"debridement"and"skin"grafting"as"well.""The" compounds" being" tested" in" this" thesis" are" nicotinic" acid," erythroZguaiacylglycerolZ8ZOZ4’Zconiferyl"alcohol"(T1)"and"naringenin.""Nicotinic"acid"has"previously" been" demonstrated" to" be" proZangiogenic" by" stimulation" of" the"nicotinic"acetylcholine"receptors" (nAChRs)"on"vascular"endothelial" cells"and"by"inducing"an"increase"in"the"growth,"morphology"and"function"of"endothelial"cells.""Nicotinic" acid" has" been" reported" to" elicit" responses" that" are" characteristic" of"those" induced" by" endogenous" angiogenic" factors.(92," 95)" " For" example,"experimental"data"in"diabetic"mice"performed"by"Jacobi"et#al.#demonstrated"that"after" 14" days," nicotinic" acid" treated" wounds" showed" an" approximately" 77%"wound"closure"rate"compared"to"an"approximately"35%"wound"closure"for"nonZtreated" wounds.(92)" " It" has" also" been" demonstrated" that" nicotinic" acid" reduces"endothelial" cell" apoptosis" and" causes" morphological" changes" to" endothelial"monolayers" identical" to" that" observed" with" VEGF.(91)" "Accelerated" healing" was"also"observed" in"mouse"studies"combining"FGF"and"nicotine.(93,"96)""FGF"has"also"
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been"identified"as"an"accelerated"healing"agent"in"diabetic"wounds.(96))"
1.7)Flavonoid1based)and)Lignan1based)Pro1Angiogenic)Compounds:)Naringenin" and" T1" (erythroZguaiacylglycerolZ8ZOZ4’Zconiferyl" alcohol)" are"flavonoidZbased" and" lignanZbased" compounds," respectively," with" T1" being"developed" at" the" John" Curtin" School" of"Medical" Research" by" Prof." Chris" Parish"and"associates.""Prof."Parish"and"his"associates"have"shown"that"both"naringenin"and" T1" are" capable" of" increasing" angiogenesis" in# vitro," but" have" not"demonstrated" that" these" compounds" elicit" this" effect" in# vivo.(97)" " It" is"hypothesized" that" both" naringenin" and" T1" may" posses" bFGFZlike" stimulatory"activity"and"may"enhance"angiogenesis"via"FGF"signalling"pathways.(96,"97)""Flavonoids" (or" bioflavonoids)" are" a" class" of" polyphenolic" secondary" plant"metabolites"and"were"initially"known"as"Vitamin"P"and"Vitamin"C2"in"the"1930s.""The"vitamin"claim"was"abandoned"in"the"1950s.(98,"99)""Flavonoids"are"present"in"varying"levels"in"fruits,"vegetables"and"beverages"(tea,"coffee,"beer,"wine"and"fruit"drinks).(100)""Flavonoids,"however,"cannot"be"synthesized"by"mammalian"cells"and"must"be"obtained"solely"from"dietary"sources.""Flavonoid"pigment"is"responsible"for" the" colour" seen" in" leaves.(97,"101,"102)""Over"4,000" flavonoids"have" so" far"been"identified.(100)" "Flavonoids"were"of"initial"interest"when"it"was"discovered"in"the"1930s" that" they" decreased" vessel" permeability" and" had" Vitamin" C" sparing"properties.""After"a"60"year"hiatus,"flavonoids"reZemerged"in"a"Dutch"study"when"it"was"shown"that"dietary"intake"of"flavonoids"was"inversely"related"to"coronary"heart"disease"incidence.(99)"
"
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Flavonoids"are"readily"absorbed"from"the"gastroZintestinal"tract"in"humans"with"major" sites" of" metabolism" occurring" by" colonic" flora" and" in" the" liver.(103)""However,"a"study"by"KrisZEtherton"et#al."showed"the"bioavailability"of"flavonoids"to" be" <1%," thus"making" the" oral" route" of" any" therapeutic" intervention" appear"unreliable" and" unrealistic." " This" further" reinforces" the" use" of" flavonoids" as"topicallyZapplied"compounds"when"dealing"with"wounds"that"are"slow"to"heal.(97,"
104)"""Flavonoids"can"be"divided"into"six"main"classes"(Figure"13):"1. Flavonols"2. Flavones"3. Isoflavones"4. FlavanZ3Zols"5. Flavanones"6. Anthocyanidins.(98,"99)""
"Figure"13:"Six"main"classes"of"Flavonoid.(99)""
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As"flavonoids"are"commonly"found"in"many"staple"fruits"and"vegetables,"it"is"also"believed" they" posses" potent" antioxidant" activity" as" the" aromatic" rings" of" the"flavonoid" allow" for" the" donation" and" acceptance" of" electrons" from" free" radical"species.(99)""It" is" this" ability" to"protect" cells" against" the"damaging"effects"of" free"radical" production" that" has" also" revived" flavonoid" prominence.(100)" These"properties" account" for" their" role" in" protecting" against" coronary" artery" disease"and"certain"types"of"cancer.(99,"100)""""Lignans" are" polyphenols," again" found" in" plants," which" are" preZcursors" of" the"polymer" lignin." " Lignans" are" found" in" seeds," wholeZgrains," legumes," fruits" and"vegetables," with" flaxZseeds" being" the" richest" dietary" source.(105)" " Lignan"precursors" are" converted" into" enterolignans," enterodiol" and" enterolactone" by"intestinal" bacteria." " Enterodiol" and" enterolactone" are" weak" oestrogenZlike"compounds"exerting"their"effects"through"nonZoestrogenic"mechanisms.""Lignans"are" the"main"source"of"dietary"phytoestrogens" in" the"Western"diet.(105)"Lignans"have" aroused" significant" interest,"with" some" studies" suggesting" that" they" have"potential" antiZoestrogenic" effects" on" oestrogen" receptor" positive" breast"cancer.(106)""One"of"the"main"mechanisms"suspected"for"this"is"the"suppression"of"angiogenesis"in"solid"tumours.""However,"Prof."Parish"and"associates"at"ANU"have"discovered" in" previous" studies" that" at" differing" concentrations" lignans" can"enhance" angiogenesis" in# vitro," although" in" these" experiments" the" unmodified"lignans"were"used"that"had"not"been"converted"by"intestinal"bacteria.""Hence,"in"their"unmodified" form," they"are"a"potential" therapeutic"class"of"compound"that"can"positively"augment"the"rate"of"angiogenesis"in"healing"wounds.""
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1.7.1)Naringenin:)Naringenin" (5,7ZdihydroxyZ2Z(4Zhydroxyphenyl)chromanZ4Zone)," is" a" nonZprenylated" flavanone" found"primarily" in"citrus" fruit." " ‘Prenylation’" refers" to" the"postZtranslational"modification"of"a"molecule"with"isoprenyl"anchors,"in"proteins"usually" occurring" at" or" near" a" carboxyl" terminal" cysteine" residue." " These" lipid"moieties" are" typically" involved" in" mediating" proteinZmembrane" (cell)" and"proteinZprotein" interactions(107," 108)" –" or" put" simply," the" addition" of" a"hydrophobic"molecule" to" a" protein" allowing" for" proteinZcell" or" proteinZprotein"interactions." " Studies" have" already" demonstrated" that" naringenin" has" a" role" in"inhibiting" VEGF" in" human" tumour" cells," thus" having" a" potential" role" in" breast"cancer" treatment" by" inhibiting" tumour" angiogenesis.(109)" " Naringenin" has" also"been"shown" to" suppress" colon"carcinogenesis" in" susceptible" laboratory" rats"by"reducing" high" multiplicity" aberrant" crypt" foci.(110)" " Naringenin" may" also" have"intracellular"properties"whereby"DNA"repair"can"be"encouraged." "Studies"show"that" naringenin" applied" to" prostate" cancer" cells" stimulates" DNA" base" excision"repair," preventing" further" mutagenic" changes" in" already" cancerous" prostate"cells.(111)" "An" important" feature" of" flavonoids," however," is" that" they" are" usually"extensively"metabolised"in#vivo"to"yield"byproducts"that"mediate"their"biological"effects," the"parent"compound"producing"effects" in#vitro" that"may"not"be"seen" in#
vivo" unless" the" flavonoids" is"being"administered" topically," as" is" the" case" in" this"thesis,"to"treat"local"skin"conditions"and"wound"healing.""The"chemical"structure"of"naringenin"can"be"seen"in"Figure"14." "Naringenin"has"been"generally" thought" to"be"antiZangiogenic,"but"at"very" low"concentrations" it"has"been"shown" to"be"proZangiogenic,"based"on" in#vitro" testing"by"Prof."Parish,"
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Prof" Djordjevic" and" PhD" student" Ms" Farzaneh" Kordbacheh" at" the" ANU" at"concentrations" in" the" 10Z6M" to" 10Z8M" range.(97)" " Furthermore," naringenin" was"found"to"enhance"endothelial"cell"proliferation"and"tube" formation,"particularly"when" bFGF" was" present." This" makes" naringenin" a" suitable" compound" to" be"tested" in#vivo," particularly"with" regards" to" accelerating" angiogenesis" in"wound"healing"where"it"is"topically"applied"and"not"subjected"to"chemical"modification.""However,"it"should"be"noted"that"naringenin"is"unique,"a"considerable"number"of"other"flavonoids"being"tested"by"the"Parish/Djordjevic"labs"and"shown"in#vitro"to"be"either"antiZangiogenic"or"inactive."
"Figure"14:"Chemical"structure"of"naringenin.(112)"
)
1.7.2)T1)(Erythro1guaiacylglycerol181O14’1coniferyl)alcohol):)T1" (erythroZguaiacylglycerolZ8ZOZ4’Zconiferyl" alcohol)" belongs" to" the" lignan"family"of"molecules."It"is"a"novel"compound"identified"in"the"sap"of"soya"beans"by"the" Parish/Djordjevic" labs" and" has" been" shown" to" be" a" water" soluble," proZangiogenic"compound"in#vitro,"but"lacks"in#vivo#testing.""In"the"studies"reported"in"this"thesis"it"was"decided"that,"based"on"the"in#vitro"data,"T1"would"be"tested"for"
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wound" healing" enhancement" at" two" topical" concentrations," 10Z7M" and" 10Z8M.""Previous" studies" by" PhD" student," Ms" Farzaneh" Kordbacheh," have" shown" the"positive" effects" of" syntheticallyZderived" T1" on" serumZstarved" human" umbilical"vein" endothelial" cell" (HUVEC)" proliferation" in" serum" free" media," particularly"when" coupled"with" bFGF" (12.5ng/ml)." " This" combination" induced" a" significant"cell"proliferation"result"after"only"24"hours"of"incubation.(97)""Ms"Kordbacheh"also"demonstrated"that"T1"significantly"enhanced"tube"formation"by"HUVEC"cultured"on"the"artificial"basement"membrane,"Matrigel,"in"the"presence"of"bFGF.""HUVEC"tube" formation" was" also" enhanced" without" bFGF," but" to" a" lesser" degree.""However," T1" appeared" to" have" no" measurable" effect" on" the" speed" of" in# vitro"wound"closure"in"an"assay"using"HMEC"(human"microvascular"endothelial"cell)."This"assay" involved"denuding"a" strip"of" a"HMEC"monolayer"and"measuring" the"speed"with"which"the"HMEC"migrated"and"‘closed’"the"denuded"area.(97)""Hence," Ms" Kordbacheh’s" PhD" results" drew" the" conclusion:" “Therefore,# as#
synthetic#T1#did#enhance#HUVEC#proliferation#and#tube#formation#in#the#absence#of#
bFGF#and#as#HUVEC#proliferation#was#even#greater#in#the#presence#of#bFGF,#it#can#
be#hypothesized#that#these#molecules#have#similar#functions#to#bFGF#in#enhancing#
angiogenesis# directly# rather# than# through# activation# of# integrin.mediated#
attachment.”(97)"""Previous" studies" have" already" confirmed" the" ability" of" bFGF" to" enhance"angiogenesis" and" granulation" tissue" formation." " For" example," a" study" by"Okumara" et# al." showed" that" bFGF" has" a" doseZdependent" enhancement" on"granulation" tissue" in" healingZimpaired" rats." " Repeated" application" of" bFGF"
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accelerated" the" closure" of" fullZthickness" wounds" created" in" diabetic" rats.""However,"excessive"administration"of"bFGF"appeared" to" impair"wound"healing,"mainly"due"to"the"prolonged"phases"of"both"angiogenesis"and"granulation"tissue"formation.(96,"113)""The"chemical"structure"of"T1"can"be"seen"below,"in"Figure"15.""
"Figure"15:"Chemical"structure"of"T1"(erythroZguaiacylglycerolZ8ZOZ4’Zconiferyl"alcohol).(97)""
)
) )
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Chapter)2:)Study)Hypothesis)and)Objectives)
2.1)Objectives)and)Hypothesis:)The" objective" of" this" study" is" to" further" research" novel," topically" applied"compounds"that"may"accelerate"angiogenesis"in"wounds"leading"to"faster"healing"rates." "This" increased"rate"of"healing"will"decrease" the"amount"of" time"wounds"are"susceptible"to"infection,"especially"in"regards"to"the"impairment"that"diabetes"causes" to" healing" by" decreasing" growth" factor" production," angiogenesis,"macrophage"recruitment,"collagen"accumulation"and"fibroblast"migration.(8,"45,"60)""The" hypothesis" is" that" if" the" rate," quality" and" quantity" of" blood" vessel" growth"(angiogenesis)"in"a"wound"can"be"augmented"then"wounds"will"heal"faster"with"reduced"healthcareZrelated"costs."""
2.2)Primary)Objectives:))
• Identify"and"test"compounds"that"may"accelerate"angiogenesis."Professor"Christopher"Parish"at"the"John"Curtin"School"of"Medical"Research"supplied"these" compounds," which" in# vitro" have" been" shown" to" possess" positive"angiogenic"and"bFGFZlike"properties."
• Reproduce" a" reliable" model" of" wounding," wound" documentation" and"assessment"of"healing"in"the"adult"mouse."
• Compare" all" experimental" compounds" against" results" generated" by" a"control"receiving"compound"diluent"(PBS)"alone."
• Analyse" histological" features" of" wounds" for" levels" of" angiogenesis" and"other"key"aspects"of"wound"healing."
)
56""
2.3)Secondary)Objectives:)
• Identify"optimal"concentrations"at"which"novel"compounds"may"produce"maximal"angiogenesis/biological"effects."
• Determine" if" trialled" compounds" have" a" role" in" inflammation" and"neutrophil"signalling.""
)
)
)
)
)
)
)
)
)
)
)
)
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Chapter)3)Materials)and)Methods:)
3.1)Optimal)Angiogenesis)Analysis:)Angiogenesis"during"wound"healing"is"a"highly"orchestrated"event.""Not"only"does"angiogenesis"occur"in"three"dimensions"but"the"fourth"dimension"of"time"is"also"extremely" critical" to" successful" angiogenesis" and" wound" healing." " It" has" been"shown"that"at"between"3–5"days,"a"wound"which"heals"by"secondary"intention"is"filled"with"granulation"material"and"that"angiogenesis"is"maximal"at"this"point.(60,"
114,"115)""Conversely,"when"woundZhealing" reaches" the" second"week,"wounds"are"largely" comprised" of" collagen" and" ongoing" fibroblast" proliferation.(60)" " The"leukocytic" infiltrate," oedema," and" aforementioned" angiogenesis" have" largely"disappeared.(60)" "To" avoid" potential" false" negatives" concerning" angiogenesis," it"was" proposed" that" the" studies" reported" in" this" thesis" would" include" a" second"group" of" wounds" that" would" be" analysed" after" the" initial" assay." " This" second"assay"again" incorporated"a"control,"phosphate"buffered"saline" (PBS)" treatment,"with" T1" and" naringenin" applied" at" their" highest" concentrations." " This" second"phase"was"run"as"per"the"first,"except"the"wounds"were"harvested"at"Day"3,"the"first" day" of" maximal" angiogenesis.(60," 114," 115)" " Various" methods" were" used" to"analyse"angiogenesis"in"this"second"group.""The"first"group"of"animals"had"their"wounds"analysed"after"they"had"healed"or"at"Day" 12" of" the" experiment." " Healing" was" expected" to" occur" within" 12" days,"depending"on" the" angiogenic" activity"of" the" compounds" tested." "Once" a"wound"was"deemed"healed"by"optical"analysis"(wound"size"reduction">98%),"the"wound"was" harvested" and" sent" for" histological" fixation." " The" wounds" were" analysed"
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using" haematoxylin" and" eosin" (H" and" E)" staining." " H" and" E" staining" has" been"available" for"over"one"hundred"years"and" is"an"essential"histological"process" in"identifying"morphological" changes" in" tissues." "H" and"E" staining" is" essential" for"elucidating" cytoplasmic," nuclear" and" extracellular"matrix" features.(116)" " Basic"H"and"E"staining"enabled"the"counting"of"the"number"of"fibroblasts"per"high"power"field.""A"scoring"mechanism"identifying"key"features"of"wound"healing"was"used"(expanded" upon" later" in" Section" 4)" and" statistically" analysed" for" significance.""This"approach"is"similar"to"that"used"in"the"Greenhalgh"et#al."study,"but"identified"more" key" features" associated" with" wound" healing," such" as" angiogenesis,"collagenZdeposition"and"granulation"tissue"quality.(94)""Angiogenesis" scoring," however," requires" a" second" immunohistochemical" stain"using"a"monoclonal"antibody"(mAb)"specific"for"mouse"CD34." "CD34"is"a"singleZchain" transZmembrane" glycoprotein" (105–120" kilodaltons)" present" on"endothelial" cells," immature"haematopoietic"precursor" cells" and"haematopoietic"colonyZforming" cells" in" bone" marrow" and" blood.(117)" " Peripheral" blood"lymphocytes,"monocytes,"granulocytes,"and"platelets"do"not"express"CD34"and"its"density" is" highest" on" early" haematopoietic" progenitor" cells," decreasing" as" the"cells"mature." " The" antigen" is" absent" on" fully" differentiated"hematopoietic" cells,"thus" avoiding" confusion" with" the" CD34" staining" of" already" existing" vascular"structures.(117)" "The"use"of"a"mouse"antiZCD34"specific"antibody"stain"only" took"place"after"H"and"E"staining"showed"sufficient"evidence"of"neoangiogenesis.""The"use"of"the"CD34"immunohistochemical"stain"enables"investigators"to"objectively"quantify" the"number"of"blood"vessels"present"per"high"power" field" in"a" similar"method"to"traditional"cell"counting."
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Digital" images" of" the" high" power" fields" were" collected" from" the" harvested"wounds." " These" digital" pictures"were" then" analysed" using" ImageJ®" to" identify"and"quantify"coloured"pixels.(118)""Pixel"counts"were"then"statistically"analysed"to"determine"whether"a"significant"level"of"angiogenic"activity"existed"between"the"different"groups"at"Day"3.""Trichrome"staining"was"also"performed"to"determine"collagen"deposition"levels."
3.2)Mouse)Angiogenesis)Model)and)Surgical)Technique:"The" most" common" and" readily" selected" model" for" cutaneous" healing" and"angiogenesis" studies"using" topical" compounds"has"been" the"mouse"model.(67,"70,"
71,"82,"92Z94,"120Z123)""Mice"have"a"number"of"advantages"over"other"laboratoryZbased"animals"in"that"they"are"small,"inexpensive,"easy"to"care"for,"have"short"breeding"spans"and"have"for"a"long"time"been"used"as"a"proxy"for"human"skin"studies"and"experiments"involving"mammalianZbased"research." "Since"the"sequencing"of"the"mouse" genome," the" creation" of" additional" genomic" and" genetic" resources" will"only" continue" to" add" value" to" the" mouse" model" of" research.(124)" " The" mice"selected" for" the" experiments" described" in" this" thesis" were" C57BL/6J" mice,"commonly" known" as" BlackZ6." " BlackZ6" mice" are" the" most" widely" used" inbred"strain"and"were"the"first"to"have"their"genome"completely"sequenced.(125)""Female"C57BL/6"mice"were"used,"as"they"are"less"aggressive"and"thus"less"disruptive"to"wounds.""Studies" on" applying" topical" wound" healing" compounds" from" the" early" 1990s"pioneered"a"method,"very"similar"to"that"undertaken"in"this"research"project.""It"was" hoped" that" the" results" of" this" research"would" be" eventually" applicable" to"
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diabetics," but" for" the" interim," nonZdiabetic" C57BL/6J" mice" were" used" for" this"study." "This"conclusion"is"based"on"the"premise"that" if" topically"applied"healing"compounds"can"succeed" in"healthy"animals," then" logically" this"may"translate" to"accelerated"healing"in"diabetic"animals.""""Research"conducted"by"Greenhalgh"et#al.#developed"a"model"where"diabetic"mice"were" anaesthetised," depilated," skin" prepared" with" pivodineZiodine" and" a" fullZthickness"15"x"15"mm"wound"created"on"their"back.(94)""Wounds"were"then"traced"onto"a"blank"slide"to"provide"an"initial"recoding"of"wound"surface"area.""Wounds"were"measured"at" specific" intervals"using" the" same"method"and" then"analysed"using"ImageMeasure®.""The"compounds"trialled,"PDGF"and"FGF,"were"then"added"after" initial"wounding." " The"wounds"were" then" reZmeasured"when" the" animals"were" euthanised" at" set" time" intervals" and" a" percentage" calculation" of" wound"healing" was" determined" by" pixelZbased" counting" techniques" using"ImageMeasure®." "The" technique"has"now"evolved" to" include"highZgrade"optical"equipment" and" computer" analysis" software" that" is" widely" disseminated." " For"example," Galliano" et# al.# performed" a" similar" experiment" using" topical"recombinantZVEGF"on"diabetic"mice,"studying"wound"healing"and"recruitment"of"boneZderived" angiogenic" cells." " In" Galliano’s" experiment," the" full" thickness"wound"was" created"with" a" human"dermal" punch"biopsy" and" a" 12"mm"silicone"ring"sutured"around"the"wound.""A"picture"was"taken"every"second"day"and"the"pixelZcount"analysed"using"SigmaScan®(82).""The"silicone"ring"acted"as"a"constant"reference" point" in" the" experimental" process" allowing" for" calibration" of" pixelZcounts"at"varying"focal"lengths.""
61""
A"combination"of"methods"from"both"these"experimental"approaches"formed"the"pictorial" recording"component"of" the"wound"healing"research"described" in" this"thesis.""In"these"experiments,"a"highZresolution"digital"SLR"camera"was"used"at"a"fixed" focal" length," operated"by" remote" shutter" control" (to" avoid"vibration)" and"mounted"on"a"commercially"available"biZdirectionally"illuminated"camera"stand.""The" resolution"of" the" image"was" also" enhanced"by" the"use"of" a"Nikon®"40"mm"f/2.8G"DX"MicroZNIKKOR"lens.""The"use"of"a"microZlens"enabled"greater"than"1:1"magnification"of" the"wound"allowing" for" increased"sensitivity" in"discriminating"wound" margins," especially" epithelial" leading" edges." " The" images" were" then"analysed" using" the" pixelZbased" program" ImageZJ®" which" is" a" free," freeware"program" developed" by" the" National" Institute" of" Health.(126)" " Analysis" of" the"wounds" in" this"manner" reinforced" accuracy" and" objectivity"when" determining"the"rate"at"which"wounds"healed"macroscopically."
)
3.3)Animal)Care:)In"previous"studies,"in"research"conducted"by"Galliano"et#al.#and"Greenhalgh"et#al.#respectively(82," 94),"methods" of" protecting" the" wounds" created" on" experimental"animals"involved"suturing"and"the"use"of"chemical"adhesives"creating"protective"barriers." " In" the" current" study" described" in" this" thesis," suturing" or" use" of"chemical"adhesives"was"thought"to"be"restrictive"for"the"animals"and"a"previous"effective"study"published"by"Werner"et#al.#yielded"successful"results"without"the"need"for"the"two"measures"mentioned"above.(127)"
"All" C57BL/6J"mice" involved" in" this" research"project"were" aged"6–8"weeks" and"were" housed" in" a" central" animal" facilities" at" The" Canberra" Hospital" or" at" The"
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Hugh"Ennor"Building,"Australian"National"University"main"campus." "Cages"were"connected" to" a" central" ventilation" system" and" a" 12" hour" light/dark" cycle"maintained." "Food"and"water"were"provided"ad#libitum." "Housing"of"the"animals"complied" with" Australian" National" University" Animal" Ethics" Protocols," with"animals"being"placed"in"isolation"cages"to"avoid"wound"contamination"by"the"coZpresence" of" groomer" or" aggressive" animals." " FullZtime" animal" care" technicians"monitored" the" animals" for" signs" of" distress" with" analgesia" being" given" as"appropriate"throughout"each"experiment." "A"standardized"animal"welfare"sheet"as"currently"used"by"Australian"National"University"and"The"Canberra"Hospital"animal" facilities" was" employed" with" adverse" events," behaviour" or" clinical"condition" scored" as" per" the" protocol," resulting" in" immediate" euthanasia" of" the"animal" if" required." " The" animals"were" euthanised" at"Day"12"of" the" experiment"using"either"the"carbon"dioxide"insufflation"technique"or"cervical"dislocation.""All"mice"used"in"the"wound"healing"experiments"required"surgical"procedures"to"be" performed" in" accordance"with" the" requirements" of" The"Australian"National"University:" Animal" Experimentation" Ethics" Committee," with" suitable" and"acceptable"anaesthetic"and"analgesia"provided.(128)" " In"previous,"similar"studies,"it" has" been"well" demonstrated" that" intraperitoneal" injections" of" pentobarbital,"fluanisone,"fentanyl,"ketamine,"xylazine"or"a"combination"of"similar"anaesthetic,"analgesic" and" hypnotic" compounds" can" be" used" successfully.(94," 122," 123," 129)""Initially," intraperitoneal"ketamine," in"combination"with"local"anaesthetic"was"to"be"used.""However,"given"the"complex"and"difficulties"associated"with"temporary"S8"licensing"and"adequate"safe"storage"facilities"an"alternative"was"sought.""
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The" search" for" an" S8" alternatives" is" mentioned" by" The" Australian" National"University:"Animal"Experimentation"Ethics"Committee." "For"example,"“Ketamine#
is# used# usually# in# combination# with# other# agents,# but# sometimes# alone.# # It# is# a#
dissociative# anaesthetic# agent# and# its# biggest# use# at# the# Australian# National#
University# is# in# combination# with# Rompun# (xylazine)# as# an# anaesthetic# for#
rodents”.(130)##Alternatives"by"species"(for"mice)"are"inhalation"anaesthetics"with"Isoflurane"administered"with"the"appropriate"vaporiser"being"favoured.(130)""""After" consultation" with" The" Australian" National" University:" Animal"Experimentation" Ethics" Committee," Animal" House" Management" Staff" and" the"Australian" National" University" Veterinarian," a" combination" of" inhalation" gas"anaesthesia" (Isoflurane)," subcutaneous" Metacam®" (Meloxicam," a" common"veterinary" nonZsteroidal" antiZinflammatory" [NSAID])" and" the" oral" paediatric"formulation"Nurofen®"(Ibuprofen"–"Human"NSAID)"was"deemed"appropriate.(131Z
133)""This" removed" the" requirement" for"an"S8" licence" for" the"primary" labZbased"investigator.""""Anaesthetic" training" was" undertaken" at" The" Canberra" Hospital" under" the"supervision" of" the" Australian" National" University" Animal" Ethics" Manager" Ms"Kelly" Debono." " Initially" animals" were" anaesthetised" using" a" small" induction"chamber"using"5%" isoflurane." "The"use"of" an" induction" chamber"and"a"general"anaesthetic" aided" in" reducing" stress" on" the" animals" as" this" is" a" major" factor"regarding"successful"wound"healing,"as"stressed"animals"do"not"heal"as"well"as"unstressed"animals.(134)""The"use"of"a"general"anaesthetic"agent"also"removed"the"requirement"for"animals"to"have"an"intraZperitoneal"injection,"further"avoiding"a"
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painful" stimulus" and" potential" infection" that" would" adversely" affect" animal"welfare.""""Isoflurane" is" a" widely" used" volatile" anaesthetic" and" is" a" halogenated" ether.""Isoflurane" has" the" potential" to" cause" hypotension" and" it" is" also" a" powerful"coronary" vasodilator.(135)" " Isoflurane" can" be" a" slight" irritant" to" the" respiratory"tract;" thus" careful" monitoring" of" the" animals" postZoperatively" was" observed,"especially" for" animals"displaying" signs"of" respiratory"distress.(135)""However," an"appreciable" advantage" of" isoflurane"when" compared" to" older" anaesthetics" like"enflurane"is"that"it"lacks"proZconvulsive"activity.(135)"""Prior"to"surgery,"the"mice"were"anaesthetised"within"an"induction"chamber"with"an" oxygen" flow" rate" of" 1" L/minute." " Once" anaesthetised," the" mouse" were"removed" from" the" chamber" and" placed" onto" a" small" animal" zero" dead" space"mask" system" with" a" rate" of" 3%" isoflurane" with" an" oxygen" flow" rate" of" 0.1"L/minute." " For"wound"dressing" and" assessment," postZsurgery"mice"were" again"anaesthetised"and"induced"as"above;"however"the"maintenance"rate"via"the"mask"was"reduced"to"2%"isoflurane.""Mice"were"kept"warm"throughout"anaesthesia"by"the"use"of"an"animal"heat"pad,"with"a"heat"pad"also"being"placed"under"the"cage"postZsurgery"until"the"mice"had"fully"recovered.""Mice"were"monitored"until"they"had"fully"recovered"from"anesthesia.""At"the"same"time"as"initial"anaestheisa"and"wounding," a" subcutaneous" dose" of" Metacam®" was" given." " The" Metacam®"was"diluted"1:10"using"sterile"water"for"injection"and"was"given"subcutaneously"with"a" 26g" needle" at" 1" mg/kg" periZoperatively.(136)" " This" single" dose" of" Metacam"covered"the"animals" for"24"hours." "Adhering" to" the"animal"analgesia"guidelines"
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specified,"this"treatment"did"not"exceed"3"days,"avoiding"the"unwanted"decrease"in" appetite," renal" blood" flow" and" cardiovascular" or" gastrointestinal" sideZeffects.(136)""
"All" NSAID" class" drugs" have" three" main" therapeutic" effects," being" antiZinflammatory," analgesic" and" antiZpyretic." " Metacam®"as" mentioned" above," is" a"common" veterinary" analgesic" but" is" mainly" used" in" humans" for" its" antiZinflammatory" properties," namely" in" the" treatment" of" rheumatic" diseases.(135)""There" is" a" slight" tendency" for" NSAIDs" to" prolong" bleeding" time" through" the"inhibition"of"platelet"function.""However,"platelet"inhibition"is"not"a"concern"with"selective" cycloZoxygenaseZ2" inhibitors" such" as" Metacam®.(135," 137)" " Surgical"haemostasis"was"achieved"prior"to"animals"commencing"the"recovery"phase.""On"the" first" postZoperative" day," oral" analgesia" was" used" in" the" form" of" dissolved"children’s"Nurofen®." "Nurofen®"has"a"much"broader"range"of"actions,"with"postZoperative"pain"being"a"strong"indication.(135)""It"has"been"shown"in"the"literature"that"dissolved"Nurofen"at"doses"of"7.5"mg/kg"to" 30" mg/kg" has" been" successful" in" treating" mild" to" moderately" painful"conditions"such"as"skin"lesions,"fight"wounds"and"eye"abscesses"in"mice.(138)""On"Day" 3," the"water" containing" the" dissolved"Nurofen®"was" replaced"with" normal"water" to"avoid" the"unwanted"effects"of"prolonged"NSAID"use." " It"has"also"been"shown"that"all"solutions"of"ibuprofen"are"stable"throughout"a"period"of"up"to"14"days," retaining"at" least"90%"of" their" initial" concentration.(139)" "This" anaesthetic"and"analgesic"regime"was"successfully"trialled"prior"to"commencement"of"formal"
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experimentation" and" the" preliminary" findings" reported" back" to" The"Australian"National"University"Animal"Experimentation"Ethics"Committee.""Experimental"animals"used"in"this"study"were"female"C57BL/6J"mice"divided"into"two"phases." "The"Phase"1,"main"assay"animals"had"a"mean"weight"="17.9"grams"(ranging"14.6" to" 21.2" grams)." " Phase"2" animals"were"not"weighed" as"weighing"this"group"was"not"essential"to"experimental"data"collection.""The"first"half"of"the"of" the"Phase"1"animals"were"operated"on"and"housed"at"The"Canberra"Hospital"Animal"Research"Laboratory"and"after"this"the"remainder"of"Phase"1"animals"and"the" entirety" of" Phase" 2" experimentation" was" conducted" at" The" Hugh" Ennor"Building" at" The" Australian" National" University." " This" move" was" necessary" as"heavy" construction"work" at" The" Canberra" Hospital" site"would" have" interfered"with"experimental"results"due"to"high"levels"of"noise"stressing"research"animals.""Australian" National" University" Animals" Ethics" Committee" Approval" (Protocol"A2011/005)" was" sought" and" gained" before" any" animal" interaction" was"undertaken," with" university" veterinary" input" also" included." " The"mice" used" in"this" experiment" were" housed" individually" in" single," centrallyZventilated" cages,"exposed" to" a" 12Zhour" light/dark" cycle," supplied" with" food" ad# libitum" and"supervised"by"animal"welfare"technicians.""Pharmacological"agents"required:"1. 5%"Isoflurane"inhalation"anaesthetic"was"used"for"both"mouse"induction"and"maintenance"of"general"anaesthesia."
67""
2. 70%" isopropyl" alcohol" wipes" for" surgical" site" sterilisation" and"preparation."3. Metacam®"diluted"1:10"in"sterile"water"to"be"given"subcutaneously"with"a"26g"needle"at"1"mg/kg"periZoperatively."4. Children’s"Nurofen®"dissolved"in"drinking"water"to"be"delivered"at"doses"of"7.5"mg/kg"for"3"days"postZoperatively."5. Phosphate"buffered"saline"solution"for"control"wound"application."6. Nicotinc"acid"(10Z4M)"for"positive"control"wound"application."7. Naringenin"(10Z6M"and"10Z8M)"for"2"experimental"groups."8. T1"(10Z7M"and"10Z8M)"for"2"experimental"groups."9. Solugel®"wound"healing"gel.""10. 10%"formalin"for"specimen"fixation.""Surgical,"application"and"anaesthetic"implements"used:"1. Basic"disposable"surgical"suturing"kits,"including"fine"scissors."2. Disposable"No."15"blade"scalpels."3. Fine"tip"surgical"marking"pen."4. 100"μL"pipette."5. Sterile"gauze."6. Kai® 6"mm"dermal"punch"biopsy"(Figure"16)."7. Basic" induction" chamber" and"maintenance" anaesthesia"machine" (Figure"17"and"18)."8. Small"set"of"electric"human"hair"clippers."""
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Image"capturing"equipment:"1. Nikon®"D3100"Digital"SLR"camera."2. Nikon®"40"mm"f/2.8G"DX"MicroZNIKKOR"(Macro)"lens."3. Nikon®"remote"control"shutter"release."4. Commercially"available"biZdirectionally"illuminated"camera"stand"(Figure"19).""Image"processing,"data"collection"and"statistical"software:"1. ImageJ®"–"Pixel"based"analysis"software."2. Microsoft"Excel"2011®"–"Raw"data"entry"and"storage."3. Statistical" Package" for" the" Social" Sciences®" (SPSS)" IBM®," Version" 20" –"Statistical"analysis"software." "
"Figure"16:"Kai® 6"mm"dermal"punch"biopsy.""
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"Figure"17:"General"anaesthetic"machine"with"induction"chamber.""
70""
"Figure"18:"General"anaesthetic"maintenance"mask"and"surgical"implements"for"wound"creation.""
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"Figure"19:"BiZdirectionally"illuminated"camera"stand"used"for"pictorial"wound"documentation."
)
3.4)Phase)1)Testing)of)Compounds)Methods:)Phase" 1" testing" represented" the" main" assay" for" the" evaluation" of" the" overall"healing" rates" for" the" control," positive" control" and" experimental" compounds.""Sixty"mice"in"total"were"required"for"this"phase"with"a"further"subZdivision"into"six"groups"of"ten.""Each"group"of"ten"was"assigned"a"compound"labelled"A,"B,"C,"D,"E" or" F." " These" names" were" given" to" the" researcher" so" as" to" blind" the" actual"compounds" and" to" eliminate" any" potential" bias" during" experimentation." " Each"compound"was" tested,"one"animal"at" a" time,"per"group." " For"example,"Group"A"was"used"on"the"first"group"of"ten"mice,"with"compounds"following"alphabetically"for"each"group"of"ten.""
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For" example," the" procedure" for" a" group" of" ten" mice" was" as" follows." " The"operating"area"and"general"anaesthetic"machine"was"prepared"and"checked"and"the"mouse"was" taken" from" its" cage" and"placed" in" the" induction" chamber." " The"general"anaesthetic"of"5%"Isoflurane"with"an"oxygen"flow"rate"of"1"L/minute"was"then" introduced" into" the"chamber." "Once" the"anaesthetic"effect"had"taken"place"the" mouse" was" positioned" on" the" operating" area" and" transferred" to" a" small"animal"zero"deadZspace"breathing"mask.""The"oxygen"flow"rate"was"then"reduced"to"0.1"L/minute"and"the"mouse"placed"on"a"heat"pad"(Figure"18).""Gentle"stroking"of"the"eyelid"and"squeezing"of"the"paws"confirmed"a"suitable"level"of"anaesthesia.""Once" full" general" anaesthesia" was" attained," the" hair" was" clipped" in" a" suitable"location"on"the"back"and"the"skin"prepped"with"a"70%"isopropyl"alcohol"wipe.""""The" left" hind" leg"was" also" prepped" and" a" subcutaneous" injection" of"Metacam®"given." " A" full" thickness" wound"was" then" created" using" a" 6"mm" dermal" punch"biopsy"on" the"prepped"back"of" the"animal." "Pressure"was"applied"as"needed" to"ensure" surgical" haemostasis." " The" mouse" was" then" transferred" and" placed"underneath" the"mounted"camera"at"a" focal" length"of"100"mm." "A"picture"of" the"wound"was"then"taken"using"the"remote"control"shutter"release.""The"mouse"was"then"placed"back"on"the"operating"field"and"a"micropipette"used"to"draw"up"and"apply"100"μL"of" compound" that"was" then"applied" to" the"wound." " Five"minutes"was"allowed"for"absorption"into"the"wound"and"a"thin"layer"of"Solugel®"was"then"applied" covering" the" wound." " Solugel®" has" been" shown" not" to" accelerate" the"healing" of" small" fullZthickness" wounds" in" horses" and" was" used" primarily" as" a"barrier"protective"method"to"seal"over"the"applied"compound.(140)"""
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Anaesthesia"was" then"withdrawn,"with" the" animal" recovering"on" a" heated"mat"and" then" returned" to" its" respective" isolation" cage." " The" animals" were" then"monitored"twice"daily"for"the"first"three"days"then"daily"until"the"twelfth"day"of"experimentation." " Observations" were"made" and" recorded" on" a" predetermined"scoring"sheet"(Tables"4"and"5).""Every"three"days,"the"anaesthetic"procedure"was"repeated"and" the"wound"pictorially"documented"again" in" the"aboveZmentioned"manner." "ReZapplication"of" Solugel®" also"occurred" at" this"point" and" the" animal"was"allowed"to"recover,"and"was"returned"to"the"respective"isolation"cage.""This"procedure"was"repeated"until"Day"12,"when"the"wound"size"was"recorded"for"the"final" time" and" the" animal" euthanised" by" either" cervical" dislocation" or" carbon"dioxide"inhalation.""Five"mice"were" then"randomly"selected"and" the"wounds"surgically"excised"and"placed" in" 10%" formalin" solution" for" histological" analysis." " This" procedure"was"repeated" for"groups"B" through" to"F."Samples"were" fixed," sectioned"and"stained"with"both"H"and"E"and"Trichrome." " Images"from"digital"photography"were"then"uploaded"and"analysed"by"using"ImageJ®"and"pixelZcounts"entered"into"Microsoft"Excel®"score"sheets.""" """""""""""
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Table"4:"PreZdetermined"scoring"sheet"for"Animal"Welfare"Monitoring."
""Table"5:"PreZdetermined"scoring"criteria"for"Animal"Welfare"Monitoring."
"""
Mouse&Monitoring&Score&Sheet&for&A2011/005&
&
Mouse&Strain&and&Number:&
Pre=surgery&weight:&
Anaesthesia&and&surgical&notes:&
&
&
Post=surgery&monitoring&
Day&
&
Assessment&criteria&
0&&
am&
0&&
pm&
1&
&am&
1&
pm&
2&
am&
2&
pm&
3& 4& 5& 6& 7& 8& 9& 10& 11& 12&
Assessor&initials& & ! & & & & & & & & & & & & & &
Weight& & ! & & & & & & & & & & & & & &
Dehydration& & & & & & & & & & & & & & & & &
Movement& & & & & & & & & & & & & & & & &
Coat&condition& & & & & & & & & & & & & & & & &
Breathing& & & & & & & & & & & & & & & & &
Presence&of&
faeces/urine&
& & & & & & & & & & & & & & & &
Nest&quality& & & & & & & & & & & & & & & & &
Surgery&site& & & & & & & & & & & & & & & & &
Metacam&given&sc& & & & & & & & & & & & & & & & &
&
Scoring&Criteria&A2011/005&
Once&a&score&of&three&is&reached,&cumulative&or&outright&the&mouse&will&be&euthansed&and&results&documented.&
Score 
Criteria 
0 1 2 3 
Weight Normal Markedly reduced growth 
5% over 24 hours 
Weight loss >15% 
(or up to 10% in 24 hours) 
Weight loss >10% over 24 
hours or >20% over time 
Dehydration Normal Skin less elastic Skin tents Skin tents, eyes sunken 
Movement Normal Slight incoordination/ 
abnormality 
Unco-ordinated, altered 
gait, reluctant to move 
Staggering, paralysis, limb 
dragging 
Coat/skin condition Normal Rough/Lack of grooming Unkempt, thin,  
Starring coat, flakey skin 
Thickened skin, scabby, 
wounds, fur missing 
Breathing Normal Rapid, shallow Rapid, abdominal Laboured, pale MM or 
blue 
Presence of faeces/urine Normal, faeces and urine 
present, food and water 
stock decreased in hopper 
(on cage base) and bottle 
Moist faeces Diarrhoea or dry faeces, 
abnormal urine 
(volume/colour) or no 
urine or faeces present 
Uncontrolled diarrhoea, 
blood in faeces. Nil urine 
or incontinent. Or no urine 
or faeces produced in 24 
hours 
Nest quality Deep nest constructed 
using available material, 
nest being utilised 
Nest constructed and in 
use but is thin and lacks 
shape and depth 
Utilises nesting material to 
rest on but has not 
shredded to construct a 
proper nest 
No nest building activity, 
no attempt has been made 
to move or utilise nesting 
material 
Surgery Site Healing normally: Evaluate 
stage of wound healing  
1. Inflammatory 
Phase (days 1-4): 
characterised by 
redness, swelling, 
pain and heat. 
2. Proliferative phase 
(days 4-42): 
characterised by 
presence of 
Signs of minor erythema 
around wound which may 
indicate inflammatory 
response to healing or 
beginning of infection such 
as early cellulitis 
Signs of evolving 
erythema around wound 
which may indicate 
infection such as cellulitis, 
systemically well 
Obvious signs of infection, 
cellulitis, puss, ulceration 
and extension of initial 
wound borders, 
systemically unwell 
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3.5)Phase)2)Testing)of)Compounds)Methods:)1. Three" groups" of" five" animals" were" used" for" the" second" phase" of" these"experiments."2. Animals"were"this"time"assigned"a"random,"blinded"order" for"compound"use.""This"was"to"further"reduce"any"potential"bias"that"may"occur."3. The" three" groups" received" three" different" treatments," namely," PBS"(control),"T1"at"10Z7M"and"naringenin"at"10Z6M." "T1"and"naringenin"were"tested"here"at"their"highest"concentrations."4. Wounding," general" anaesthesia," wound" documentation" and" animal" care"were"conducted"as"per"the"methods"above."5. The"wounds,"however,"were"excised"and"sent"for"histological"analysis"on"the"third"day"(day"of"maximal"angiogenesis)"after"wounding."
)
3.6)Post1Wounding)Analysis:)The" wounds" were" pictorially" documented" for" each" interval" of" data" gathering,"with" the" image" of" the" wound" being" uploaded" and" analysed" by" ImageJ®." " The"image"was" analysed" by" tracing" the" edge" of" the"wound" (epithelial"margin)" and"converting"this"to"a"numeric"value"(pixel"count).""The"wound"was"then"expressed"as" a" percentage" that"was" compared" to" the" initial"wound" size." " This"method" of"pictorial" documentation" has" been" extensively" used" in" previous"wound" healing"experiments.(82,"94)""Wounds" sent" for" histological" analysis" were" stained" using" H" and" E" for" basic"histological" analysis" and" with" Masson’s" Trichrome" staining" for" analysis" of"collagen"deposition.))Depending"on"results"gained"from"this"preliminary"analysis,"
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a"decision"was"made"as"to"whether"to"analyse"the"wounds"further"using"immunoZhistochemical"techniques.""Wound"histological"analysis"was"performed"by"expert"Clinical" Pathologist" Professor" Jane" Dahlstrom," Professor" of" Pathology" at" The"Canberra"Hospital." " Professor"Dahlstrom"was" blinded" to" the" compounds" being"tested," being" supplied" with" the" generic" compound" names," A" to" F," as" was" the"researcher" during" the" experimental" phases" of" this" project." " Parameters" to" be"analysed"below"were"decided"upon"after"consultation"with"Professor"Dahlstrom"and"the"researcher."""Histological"analysis"of"Phase"1"wounds"included:"
• Skin"ulceration/erosion;"
• Scab"formation;"
• Granulation"tissue"presence;"
• Granulation"tissue"depth"(superficial"and"deep);"
• Granulation"tissue"density;"
• Cavity"formation;"
• Scar"maturation"and"thickness;"
• Presence"of"mature"collagen;"
• Collagen"density;"
• Blood"vessel"presence"in"scar"surface;""
• Blood"vessel"prominence"in"scar"surface;"
• Density"of"blood"vessels;"
• Number"of"neutrophils"associated"with"and"without"foreign"material;"
• Foreign"material"presence"and"type"and;"
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• Presence"of"calcification.""Histological"analysis"of"Phase"2"wounds"included:"
• Scab"formation;"
• Granulation"tissue"presence;"
• Granulation"tissue"depth"(superficial"and"deep);"
• Granulation"tissue"density;"
• Presence"of"collagen;"
• Blood"vessel"presence"in"scar"surface;""
• Blood"vessel"prominence"in"scar"surface;"
• Density"of"blood"vessels;"
• Number"of"neutrophils"associated"with"and"without"foreign"material"and;"
• Foreign"material"presence"and"type.""The"above"parameters"were"calculated"for"each"wound"and"the"results"expressed"as"the"number"identified"per"high"power"field.""All"results"were"entered"into"and"stored" in" a" Microsoft" Excel®" file." " This" allowed" basic" data" manipulation" and"analysis." "Results"will"be"further"elaborated"on"in"the"next"section"of"this"thesis.""Results" were" analysed" in" coZoperation" with" a" qualified" statistician," Dr" Indira"Samarawickrema," Senior" Lecturer" in" Public" Health" at" The" Australian" National"University," School" of" Medicine," Canberra." " Statistical" analysis" was" performed"using" Statistical" Package" for" the" Social" Sciences" (SPSS)" IBM®,"Version"20." " The"statistical"analysis"of"the"results"will"be"further"elaborated"on"in"the"next"section"of"this"thesis."
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Chapter)4)Establishment)of)a)Wound)Healing)
Model:)
Previous"studies"have"established"a"woundZhealing"model,"as"mentioned"above.""The"initial"pilot"trial"was"of"three"animals,"with"the"surgical"technique"performed"as" described" in" Chapter" 3." The" mice" were" placed" in" separate" cages" to" avoid"potential" cross" contamination" between" animals," with" conditions" mimicking"those"planned"for"the"compound"testing"experiments.""""The" very" first" animals" were" anaesthetized" under" the" supervision" of" an" ANU"Animals" Ethics" Committee" representative," Ms" Kelly" de" Bono," to" ensure" the"adequacy"and"effectiveness"of"anaesthesia"and"analgesia.""The"surgical"technique"used" in" these" first" few" animals" called" for" improvements." " Initially" the"wounds"created"were"quite"large"with"irregular"borders"(Figure"20"below)."
"Figure"20:"Early"Wounding"with"Irregular"Borders."
79""
These" initial" tests"were" invaluable" for" refining"a" surgical" technique" to"produce"cleaner"wounds"allowing"uniform"healing"and"to"reduce"the"amount"of"variation"in"healing"that"would"be"seen"with"varying"wound"sizes.""The" animals" were" to" originally" have" a" thin" plastic" dressing" placed" over" the"wound"to"prevent"contamination"and"infection.""This"had"been"used"previously"in"similar" experiments;" however" these" other" experiments" also" used" suturing" and"gluing"techniques.(82,"94)""It"was"felt,"however,"that"these"techniques"would"be"too"restrictive"for"the"animals"and"it"was"hoped"simple"adhesive"dressings,"like"those"used"on"humans"wounds,"would"be"adequate.""The"dressing"would,"additionally,"be" attached" to" the" wound" using" Tincture" of" Benzoin." " However," after" animals"recovered"consciousness,"the"dressing"was"found"to"be"quite"distressing"to"them,"so" it" was" removed." " An" amendment" to" the" animal" ethics" protocol" was" sought"after"further"consulting"the"literature"and"identifying"previous"studies"which"had"successful" models" similar" to" this," without" the" use" of" adhesive" or" occlusive"dressings.(127)""The"final"procedure"used"is"outlined"in"Section"3.4"above.""
"The"following"aspects"of"the"model"such"as"wound"documentation"and"daily"care"of" the" animals"went"without" significant" incident,"with" the" initial" analgesia" and"then"the"incorporation"of"subsequent"analgesia"into"the"drinking"water"working"successfully.""As"mentioned"above,"daily"scores"measuring"numerous"parameters"were" recorded" by" independent" animal" care" workers" at" both" the" Canberra"Hospital" and" The"Hugh" Ennor" Building," ANU." " No" animals" required" premature"euthanasia"during"the"entire"study."
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Chapter)5)Results,)Statistical)Analysis)and)
Discussion:)
Results" displayed" in" this" section" include" both" representations" of" the" raw" data"obtained,"graphical"interpretation"of"these"data"and"statistical"analysis"thereof."
)
5.1)Phase)1)Wound)Pixel)Count)Results:)Phase" 1" results" are" displayed" first" in" terms" of" raw" pixel" counts" gained" from"wounding" of" the" animals" and" percentage" of" healed" wounds" at" the" sampling"period"of"3"days.""Table"6"(overleaf)"represents"the"individual"and"average"pixel"counts" for" each" day" of" the" experiment" for" each" compound" tested." " Figure" 21"presents"these"data"when"comparing"the"size"of"the"wound"to"its"original"starting"size.""
) )
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Table)6:)Wound)Pixel)Counts)at)3)Daily)Intervals)
Compound(
Day(0(Pixel(
Count(
Day(3(Pixel(
Count(
Day(6(Pixel(
Count(
Day(9(Pixel(
Count(
Day(12(
Pixel(Count(
PBS(
333361$ 126748$ 58867$ 3813$ 0$
452012$ 360620$ 197003$ 8423$ 0$
639181$ 295501$ 109190$ 2675$ 0$
437735$ 382089$ 220107$ 12005$ 314$
585689$ 538568$ 205037$ 4152$ 4945$
480952$ 255222$ 91172$ 0$ 0$
365710$ 286212$ 267084$ 96969$ 40068$
332506$ 276673$ 96218$ 6370$ 0$
418147$ 351374$ 186927$ 90970$ 6402$
490231$ 414821$ 327307$ 34456$ 0$
Average$Pixel$Count$ 453552.40$ 319223.00$ 175891.20$ 25983.30$ 5172.90$
( $ $ $ $ $
Nicotinic(Acid(10=4M(
142732$ 86115$ 74486$ 57824$ 27971$
184362$ 241245$ 181894$ 125167$ 13144$
130566$ 107223$ 54761$ 10194$ 2220$
202282$ 206804$ 247454$ 134090$ 219087$
169233$ 321659$ 279344$ 212540$ 173051$
165739$ 189209$ 165339$ 118833$ 5843$
111616$ 159410$ 50450$ 47376$ 2736$
158298$ 350075$ 357980$ 212385$ 112451$
147589$ 290215$ 300333$ 222343$ 188345$
142710$ 292417$ 278319$ 217366$ 135128$
Average$Pixel$Count$ 155512.70$ 224437.20$ 199036.00$ 135811.80$ 87997.60$
$ $ $ $ $ $
Naringenin(10=6M(
237429$ 249398$ 256738$ 246605$ 38463$
181244$ 251733$ 281068$ 216026$ 156811$
131001$ 192719$ 97413$ 18242$ 12654$
202439$ 375888$ 310297$ 142553$ 622$
240377$ 375021$ 343338$ 252573$ 223873$
121940$ 260581$ 219741$ 184560$ 16465$
113955$ 282010$ 250423$ 64082$ 66203$
125339$ 234927$ 322013$ 259938$ 58858$
277165$ 342985$ 298327$ 277627$ 263605$
172509$ 373675$ 348516$ 84747$ 1509$
Average$Pixel$Count$ 180339.80$ 293893.70$ 272787.40$ 174695.30$ 83906.30$
$ $ $ $ $ $
Naringenin(10=8M(
328838$ 52783$ 36832$ 20450$ 452$
514528$ 265385$ 54341$ 13188$ 250$
255210$ 80596$ 28590$ 17469$ 0$
257678$ 136225$ 80565$ 20584$ 320$
299000$ 113916$ 55571$ 15409$ 205$
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429368$ 322211$ 243928$ 52402$ 4974$
245691$ 69369$ 63121$ 2468$ 329$
395664$ 240098$ 199478$ 23463$ 4800$
421157$ 216506$ 138157$ 18117$ 899$
400453$ 325426$ 260009$ 48358$ 1411$
Average$Pixel$Count$ 354758.70$ 182251.50$ 116059.20$ 23190.80$ 1364.00$
$ $ $ $ $ $
T1(10=7M(
176675$ 324581$ 280342$ 223005$ 175422$
182400$ 395872$ 380472$ 344035$ 234447$
96246$ 202287$ 150583$ 77789$ 1979$
153174$ 268092$ 258460$ 227828$ 208832$
120380$ 354558$ 295469$ 215360$ 192572$
145873$ 355823$ 335123$ 294823$ 43961$
234474$ 509916$ 422500$ 314895$ 315291$
223464$ 504606$ 415942$ 286438$ 294069$
145353$ 501343$ 396104$ 251604$ 204564$
189540$ 379373$ 294702$ 209704$ 206094$
Average$Pixel$Count$ 166757.90$ 379645.10$ 322969.70$ 244548.10$ 187723.10$
$ $ $ $ $ $
T1(10=8M(
146834$ 306312$ 269017$ 153277$ 3142$
160151$ 227437$ 179503$ 122871$ 9148$
116270$ 143802$ 106753$ 17776$ 45$
122324$ 59398$ 22117$ 2866$ 122$
101660$ 143123$ 108594$ 14049$ 800$
133626$ 111866$ 21692$ 2101$ 384$
202820$ 230261$ 207617$ 167510$ 2951$
133167$ 188010$ 147491$ 10783$ 2282$
178714$ 281476$ 253061$ 174670$ 143692$
150427$ 293588$ 226042$ 117224$ 304$
Average$Pixel$Count$ 144599.30$ 198527.30$ 154188.70$ 78312.70$ 16287.00$""
) )
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""Figure"21"highlights"that"that"PBS"and"naringenin"at"10Z8M"can"be"seen"to"reduce"wound" size" at" a" consistent" rate." " The" results" for" PBS," the" control" substance,"concur" with" biological" plausibility." " Naringenin" at" 10Z8M" followed" a" similar"healing"trajectory"to"PBS,"indicating"that"at"this"concentration"biological"activity"is"most" likely"negligible" to"nonZexistent." "A"pictorial"example"of"wound"healing"using"PBS"can"be"seen"overleaf"in"Figure"22.""" "
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"
"Figure"22:"Comparison"of"initial"wound"Day"0"(above)"and"healed"wound"Day"12"(below)"for"control"PBS"treatment.""
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This" conclusion" would" appear" reasonable" when" observing" the" effect" of"naringenin"at"10Z6M.""Naringenin"at10Z6M"appeared"to"increase"wound"size"with"this" effect" peaking" at"Day" 3" and" then" the"wound" decreasing" in" size" thereafter.""Nicotinic"acid"(10Z4M),"the"positive"control,"a"substance"already"proven"to"be"proZangiogenic" as" a" single" agent" and" synergistic" when" combined" with" bFGF,"increased"wound"size"at"Day"3"with"wound"size"declining"steadily"thereafter.(93)""These" findings" correlate"with" previous" studies" indicating" an" initial" increase" in"wound"size"with"various"concentrations"of"nicotinic"acid.(93)"""
"The"greatest"changes"seen"in"wound"size"occurred"for"T1"at"Day"3.""T1"at"10Z7M,"the"higher"T1"concentration"used,"appeared"to"have"the"greatest"result"overall"on"wound"size,"increasing"the"size"of"the"wounds"by"127.7%"at"Day"3"and"leaving"a"small"wound"(+12.6%)"even"at"Day"12.""A"comparison"of"wounds"at"these"critical"time"points"can"be"seen"in"Figure"23."" "
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a"
b"
c"Figure"23:"Wounds"for"T1"(10Z7M)"at"Day"0"(a),"Day"3"(b)"and"Day"12"(c)."
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It"was"decided"to"also"present"the"data"both"in"terms"of"raw"pixel"counts"and"as"percentage" size"of" original"wound,"due" to" the" initial" larger" size"of" the"PBS"and"naringenin" (10Z8M)" wounds." " The" pictorial" analysis" was" repeated" and" similar"results"obtained." " It"was" felt" that" the"main" reason" for" this"difference" in"wound"size"was"the"improvement"in"surgical"technique"that"evolved"after"the"first"two"groups"(PBS"and"10Z8M"naringenin)"had"been"completed.""An"example"of"this"can"be"seen"overleaf"in"Figure"24."""" "
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"Figure"24:"Improvements"in"surgical"technique"(above"and"below).""" "
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It"was"felt"that"this"difference"in"initial"wound"size,"however,"did"not"significantly"influence" the" conclusions" drawn" as" the"wound" healing" trends" of" both" the" PBS"and" naringenin" (10Z8M)" treated" mice" is" very" similar" (Figure" 21)." " The" results"gained"for"the"PBS"control"was"what"was"expected"biologically,"with"the"wounds"healing" naturally." " The" wounds" treated" with" naringenin" at" 10Z8M" showed"statistical"significance"for"difference"initially"at"day"zero"and"day"3,"p"="0.019"and"p"="0.015"respectively.""However,"there"was"no"statistical"difference"between"the"wound"pixel"counts"at"day"6,"9"and"12.""It"was"felt"due"to"the"similar"line"vectors"and" lack" of" endZpoint" statistical" significance" that" naringenin" at" 10Z8M" was"probably" biologically" inactive" and" that" the" small" initial" difference" was" related"primarily" to"wound" sizing" and" improving" technique." " The" statistical" analysis" is"displayed"in"Table"11"located"in"the"Appendix."
)Average"pixel"counts"were"analysed" for"all" compounds"over" the"12Zday"period.""Analysis" revealed" that" wounds" treated" with" T1" at" 10Z7M" had" a" statistically"significant"higher"pixel"count"(p"<"0.05)"at"Day"12"when"compared"to"the"control"group"(PBS).""Moreover,"T1"at"10Z7M"had"statistically"significant"differences"when"compared" to" all" other" compounds" at" Day" 12." " There" was" no" other" statistical"significant" difference" between" compounds" other" than" T1" at" 10Z7M" at" Day" 12.""This"confirmed"the"raw"data"interpretations"that"T1"at"10Z7M"appeared"to"delay"wound"healing" (Table"6" and"Figure"21)." " This" result"was" the" exact" opposite" of"that" hypothesised"with" the" final"wound" size" for" T1" at" 10Z7M" being" larger" than"initial" wounding." " Again," Table" 11" located" in" the" Appendix" shows" comparison"between"all"compounds"at"Days"0,"3,"6,"9"and"12."
)
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5.2)Phase)1)Wound)Histological)Results:"From" each" group" of"wounds" created," 5" out" of" 10"were" randomly" selected" and"sent" for"histological" analysis." " The" statistical" analysis" of"Phase"1"histology" (i.e.,"Day"12"wounds)"was"first"completed"by"analysing"each"parameter"measured"for"a" dichotomous" outcome." " For" example," there" was" a" statistically" significant"difference" in" the" outcome" for" wounds" when" granulation" tissue" level" at" both"surface" and"deep" levels"were" compared" to" outcomes" at" just" deep" level." " These"results" were" further" analysed" looking" for" any" significant" differences" between"compounds." Parameters"measured" and" scored" can" be" seen" in" Tables" 12" to" 17"located"in"the"Appendix.""The"statistically"analysis"results"are"not"displayed"in"the"main"body"of"the"thesis"again"due"to"the"Table"sizes.""These"results"can"be"seen"in"Tables" 18" to" 23." " Statistically" significant" results" determined" for" wound"histological"analysis"of"all"compounds"at"Day"12"are"displayed"concisely"overleaf"in"Table"7.""""" "
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Table"7:"Statistically"Significant"Phase"1"Wound"Histology"Results"
Histological)Parameter) Compounds)displaying)
significance)
p)1)value)
Granulation"tissue"(Superficial"and"deep)" T1"at"10Z7M"T1"at"10Z8M" <0.01"Granulation"tissue"density" PBS" 0.024"Dense"collagen"on"Trichrome"staining" T1"at"10Z7M" 0.009"Lack"of"prominent"surface"blood"vessels"in"wound" PBS"Naringenin at 10-8M" <0.01"Neutrophil"migration"to"wound">30"per"high"power"field"(not"associated"with"foreign"material)"
Naringenin at 10-6M" 0.043"
Lack"of"mature"subZepidermal"scar" T1"at"10Z7M" 0.04""Histological"examples"of"the"analysed"wounds"can"be"seen"in"Figures"25"to"28"in"the"following"pages."" "
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"Figure"25:"Mouse"B3,"an"example"of"a"control"wound"(Day"12)"from"mice"treated"with"PBS,"stained"with"H"and"E"(magnification"x4)."
"Figure"26:"Mouse"B3,"an"example"of"a"control"wound"(Day"12)"from"mice"treated"with"PBS,"stained"with"Masson’s"Trichrome"(magnification"x4)."
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For" example," as" indicated" by" the" green" arrows" in" Figures" 25" and" 26" there" is"granulation"tissue"present"only"at"the"base"of"the"wound"(H"and"E"stain)"and"only"a" moderate" degree" of" collagen" deposition" respectively" (Masson’s" Trichrome"stain)." " Contrast" this" to" the" slides" presented" overleaf" (Figures" 27" and" 28)"demonstrating" denser" levels" of" granulation" tissue" formation" and" collagen"deposition"respectively." "The"density"being"defined"as"being"present"in"both"the"superficial" and" deep" aspects" of" the" wound." " Figures" 29" and" 30" present" the"wounds"from"a"clinical"perspective"allowing"for"macroscopic"appreciation"of"the"histological"findings."" "
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"Figure"27:"Mouse"C2,"an"example"of"a"wound"(Day"12)"from"mice"treated"with"T1"at"10Z7M,"stained"with"H"and"E"(magnification"x4)."
"Figure"28:"Mouse"C2,"an"example"of"a"wound"(Day"12)"from"mice"treated"with"T1"at"10Z7M,"stained"with"Masson’s"Trichrome"(magnification"x4)."
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"Figure"29:"Mouse"B3,"an"example"of"a"wound"(Day"12)"from"mice"treated"with"PBS."
"Figure"30:"Mouse"C2,"an"example"of"a"wound"(Day"12)"from"mice"treated"with"treated"with"T1"at"10Z7M."
) )
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5.3)Phase)2)Wound)Pixel)Count)Results:)In"the"Phase"2"trial"the"effect"of"naringenin"(10Z6M),"T1"(10Z7M)"and"control"PBS"treatment" on"wound" size" and"wound" histology" at" Day" 3" after"wound" creation"was" compared," Day" 3" being" the" day" when" peak" enlargement" of" wounds" was"observed" in" the" Phase" 1" trial" with" the" two" compounds" tested." " The" Phase" 2"results" showed" that" on" average," wound" size" increased" for" all" compounds.""Naringenin"at"10Z6M"increased"wound"size"on"average"by"61.2%,"T1"at"10Z7M"by"42.0%"and"PBS"by"19.5%"(Tables"8"and"9).""There"was"a"paradoxical"increase"in"the" PBSZtreated" animals" as" it" was" expected" that" this" group" would" follow" a"healing"pattern"similar"to"the"PBSZtreated"animals"in"the"Phase"1"trial.""T1"at"10Z
7M" and" naringenin" at" 10Z6M" increased"wound" size" greater" than" PBS," but" again"paradoxical" results" were" obtained." " Naringenin" at" 10Z6M" in" the" Phase" 2" trial"increased"wound"size"more"than"T1"at"10Z7M.""""Part" of" these" results" can"most" likely" be" explained" by" the" fact" that" the" animals"used"in"the"Phase"2"trial"had"documented"Staphylococcus#aureus"contamination"as"per"Cerberus"Sciences"report"(Appendix)." "Unfortunately,"this"report"was"not"made"available"to"the"researcher"until"several"months"after"the"conclusion"of"the"experimental"phase.""Confirmation"of"potential"contamination"was"confirmed"on"histological"analysis,"with"two"of"the"animals"(one"from"T1"at"10Z7M"and"one"from"the" PBS" groups)" developing" pus" clusters." " Although," the" general" trend" of" the"trialled" compounds" increased" wound" size" corresponded" to" the" initial" Phase" 1"results," it"did"not" fully"explain"why"the"naringenin"at"10Z6M"produced"a"greater"initial"result."
) )
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Table)8:)Phase)2)Pixel)Counts)of)Wounds)at)Day)0)and)3)
Compound( Day(0(pixel(count( Day(3(pixel(count(
Pixel(count(
difference( %(difference(
PBS$ 184510$ 282361$ 97851$ 53.03$
Naringenin$(10@6M)$ 119442$ 230662$ 111220$ 93.12$
T1$(10@7M)$ 106781$ 118870$ 12089$ 11.32$
Naringenin$(10@6M)$ 125133$ 262578$ 137445$ 109.84$
PBS$ 103203$ 195249$ 92046$ 89.19$
T1(10@7M)$ 116408$ 201595$ 85187$ 73.18$
Naringenin$(10@6M)$ 179767$ 244494$ 64727$ 36.01$
T1$(10@7M)$ 181499$ 335834$ 154335$ 85.03$
PBS$ 149034$ 249290$ 100256$ 67.27$
T1$(10@7M)$ 173583$ 203137$ 29554$ 17.03$
Naringenin$(10@6M)$ 165750$ 241841$ 76091$ 45.91$
PBS$ 146985$ 113784$ @33201$ @22.59$
T1$(10@7M)$ 261126$ 332085$ 70959$ 27.17$
PBS$ 214250$ 113083$ @101167$ @47.22$
Naringenin$(10@6M)$ 121880$ 168107$ 46227$ 37.93$"
) )
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Table)9:)Phase)2)Average)Pixel)Counts)of)Wounds)and)Percentage)
Difference)at)Day)0)and)3))
PBS(
Day(0( Day(3( Avg.(pixel(count(difference( Avg.(pixel(%(difference(
184510$ 282361$
$ $103203$ 195249$
$ $149034$ 249290$
$ $146985$ 113784$
$ $214250$ 113083$ $$ $$
$
159596.40$ 190753.40$ 31157.00$ +19.52$
$ $ $ $ $
$
Day(0( Day(3( Avg.(pixel(count(difference( Avg.(pixel(%(difference(
$
119442$ 230662$
$ $
$
125133$ 262578$
$ $
$
179767$ 244494$
$ $
$
165750$ 241841$
$ $Naringenin(x10=6M( 121880$ 168107$ $ $
$
142394.40$ 229536.40$ 87142.00$ +61.20$
$ $ $ $ $
$
Day(0( Day(3( Avg.(pixel(count(difference( Avg.(pixel(%(difference(
$
106781$ 118870$
$ $
$
116408$ 201595$
$ $
$
181499$ 335834$
$ $
$
173583$ 203137$
$ $T1(x10=7M( 261126$ 332085$ $ $
$
167879.40$ 238304.20$ 70424.80$ +41.95$
)
)
) )
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Average"pixel"counts"were"analysed"for"all"compounds,"from"initial"wounding"to"the"third"day"using"the"Analysis"of"variance.""PBS"had"less"pixels"than"both"T1"at"10Z7M" and" naringenin" at" 10Z6M." " However," the" difference" was" not" statistically"significant"(p">"0.05).""On"Day"3"naringenin"at"10Z6M"enhanced"wound"size"more"than"those"treated"with"either"T1"at"10Z7M"or"PBS,"although"this"difference"was"not"statistically"significant"(p">"0.05).""Also"naringenin"at"10Z6M"created"a"larger"wound"deficit"earlier"than"T1"at"10Z7M,"contradicting"results"discovered"in"phase"1" study." " One" possible" explanation" could" have" been" the" loss" of" potency" of" the"solutions," as" fresh" compounds" were" not" prepared" for" each" phase" of" the"experiment.""Due"to"the"size,"Table"24,"the"Phase"2"PixelZcount"Statistical"Analysis"has"been"displayed"in"the"Appendix"of"this"thesis."
)
) )
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5.4)Phase)2)Wound)Histological)Results:)Statistical" analysis" of" Phase" 2" histology" was" first" completed" by" testing" each"parameter" measured" for" statistical" significance" for" its" dichotomous" outcome.""This"was" to" determine" if" the" outcome"measured" from"each"parameter" showed"significance." " Again," only" results" that" showed" significance" or" relevance" were"displayed." " The" only" significant" finding" resulting" from" the" Phase" 2" histological"analysis"was"for"that"of"granulation"tissue"level.""The"difference"between"surface"and"deep"and" just"deep"(p"="0.031)"granulation"was"significant" for"T1"at"10Z7M"(table" 10" overleaf)." " As" there" were" no" significant" changes" identified" in" blood"vessel" density," it" was" felt" there" would" be" little" benefit" in" proceeding" with"expensive"immunoZhistochemical"tests,"as"blood"vessel"prominence"should"have"been" microscopically" visible" by" the" third" day" after" wounding." " Table" 25," the"Histological"score"sheet"has"been"displayed"in"the"Appendix"of"this"thesis.""
)
) )
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Table)10:)Analysis)of)Phase)2)compounds)Tested)and)Granulation)Tissue)
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)
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No.)(%))
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5.5)Discussion:)Impaired" wound" healing" continues" to" be" an" issue" of" importance" to" clinical"practice,"especially"for"those"concerned"with"the"care"of"debilitated"patients"and"those" suffering" from" chronic" diseases" like" diabetes." " As"mentioned" previously,"impaired"wound"healing"places"not"only"an"economic"burden"on"our"society,"but"an" increased" level"of"morbidity"and" in"some"cases"mortality"on"patients,"which"may"easily"be"prevented." "Accelerating"wound"healing"would"undoubtedly"have"numerous" positive" outcomes" for" patient" care." " Various" mechanisms" and"manipulations" have" been" researched" to" try" and" achieve" accelerated" wound"healing,"but"thus"far"none"have"become"clinically"or"commercially"viable.""""The" acceleration" and" increased" proliferation" of" wound" angiogenesis" as" a"potential" therapeutic" intervention," the" notion" that" has" underpinned" this"research,"has"recently"gained"favour." "The"hope"that"successful"manipulation"of"angiogenesis" would" present" meaningful" wound" healing" responses" has" not" yet"become" a" reality." " The" compounds" tested," T1" and" naringenin," have" been"previously" shown" to" be" potential" therapeutic" enhancers" of" angiogenesis" and"bFGF"induced"proliferation"in#vitro,"but"not"in#vivo.""Unfortunately," T1" and" naringenin," which" have" both" shown" to" increase" bFGF"proliferative" activity" (potentially" an" enhancer" of" granulation" tissue)" and"angiogenesis" formation" in# vitro," have" not" produced" a" clinically" observed"acceleration" in"wound"healing"when"trialled" in#vivo." " Indeed,"quite"the"opposite"occurred," with" the" wounds" actually" increasing" in" size." " Hence," the" primary"objective"of"accelerating"wound"healing"was"not"achieved.""However,"the"results"
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gained"do"allow"for"several"interesting"observations"and"conclusions"to"be"drawn"that"may" hold" the" keys" for" future" research" into" successful," accelerated"wound"healing.""Firstly," the" mouse" model" selected" as" the" assay" of" in# vivo" healing" appeared" to"work" successfully." " Based" on" previous" models" of" wound" creation" and"documentation,"with"slight"modifications"and"Animal"Ethics"Committee"approval,"the"results"gained"appeared"to"be"reliable"overall." "Pictorial"documentation"and"digital" optical" analysis" proved" to" be" a" reliable," quick" and" accurate" method" of"assessing"wound"size"compared"to"previous"methods"of"manually"tracing"wound"edges"by"hand.(94)""This"method"also"allowed"for"easy"storage"of"data"obtained"for"future"reference.""The"most"notable"point,"however,"was"that"with"the"first"two"groups,"wound"size"documentation" in" the" Phase" 1" trials" indicated" that" these" groups" had" a" higher"initial"wound"size.""Although"the"wounds"were"larger"than"in"the"remaining"four"groups,"the"pattern"of"healing"that"followed"appeared"consistent"with"what"was"expected." " The" PBSZtreated" wound" healed" in" an" expected" and" orderly" fashion"with"the"naringenin"at"low"concentration"(10Z8M)"following"a"similar"trajectory.""The"other"compounds"tested"including"the"positive"control"of"nicotinic"acid"at"10Z
4M,"showed"increased"initial"wound"size"at"Day"3"(Figure"21).""Again,"this"finding"was"paradoxical"to"the"anticipated"results.""Nicotinic"acid"inducing"an"increase"in"wound"size"was"not"consistent"with"previous"literature"reviewed.(93)"""
"
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The"other"noticeable"effect,"especially" that"of"all"treatments"except" for"PBS"and"naringenin" at" 10Z8M,"was" that" at" the" completion" of" the" experiment" on" Day" 12"wounds"were"still"not"healed"or"in"the"case"of"T1"at"10Z7M,"were"larger"than"the"originally" sized"wound." " These" paradoxical" results"may" partly" be" explained" by"previous"findings"by"Okumura"et#al.""Okumura"found"that"the"effect"of"exogenous"FGF"on"the"wounds"of"healing#impaired"animals"resulted"in"accelerated"closure"of"fullZthickness"wounds,"enhancing"angiogenesis"and"granulation"tissue"formation"in" a" doseZdependent" manner.(113)" "The" difference" between" Okumura’s" findings"and"those"of"the"experiments"described"in"this"thesis"can"be"possibly"explained"in"several"ways.""""Firstly," the" animals" used" in" the" experiment" described" in" this" thesis" were" not"healing"impaired." "Any"factor"which"could"increase"the"rate"of"angiogenesis"and"granulation" tissue" formation" could" do" so" in" a" hyperactive"manner" in" a" normal"animal,"thus"leading"to"excessive"angiogenesis"and"granulation"tissue"formation.""This"would"seem"plausible,"as"the"wounds"treated"with"the"highest"concentration"of"T1"were"quite"large"at"the"end"of"the"twelfth"day"and"clinically"had"the"overt"appearance"of" granulation" tissue." " This" uncontrolled" granulation"would" indeed"prevent" the" wound" from" healing," as" a" highly" orchestrated" decline" in" growth"factor" activity" (including" bFGF" activity)" is" required" for" successful" wound"healing.(60)" " Secondly," Okumura" implanted" in" the" subcutaneous" tissue" of" the"animals" bFGFZimpregnated" paper" discs" at" varying" doses." " The" release" of"continued" lower" doses" may" indeed" be" linked" to" greater" granulation" tissue"control.(113)" " During" the" experiments" described" herein," although" differing"
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concentrations"of"T1"were"used,"dose"application"(100μl)"every"3"days"remained"constant.""As" the" application" of" the" trialled" compounds" did" increase" granulation" tissue"formation," it" is"hypothesised"that"further"testing"could"unlock"the"correct"doseZdependent" regime" required" to" bring" about" an" increase" in"wound"healing" time.""For" example," future" experimentation" could" test" T1," but" over" a"wider" range" of"concentrations,"and"limit"application"to"only"once"at"initial"wounding"or"at"Day"3.""The" once" only" application" would" decrease" the" likelihood" of" an" excessive"formation" of" granulation" tissue" occurring," with" Okumura" reaching" similar"conclusions" that:"Topical#application#of#excess#amounts#of#bFGF#might#reduce# its#
ability# to# promote# wound# closure# because# of# prolonged# responses# in# both#
neovascular# and# granulation# tissue# formation.(113)" " As" significant" differences" in"granulation"tissue"were"found"in"the"histological"analysis"of"T1"treated"wounds,"further"investigation"of"this"is"thus"warranted.#"Alternative"dosing"and"delivery"systems"should"also"be"considered.""For"example,"this" experiment" relied" upon" topical" dosing" for" delivery" of" compound" to" the"wound;" however" the" development" of" advanced" delivery" systems" such" as"microspheres" should" be" considered," especially" if" ‘once" only’" compound"application" is" to" be" employed." " Development" of" effective" delivery" systems" like"this" would" ensure" sustained," appropriate" release" of" required" intervention,"optimize"efficacy"and"compliance,"and"reduce"potential"sideZeffects.(141)""
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With"regards" to"angiogenesis" in" the"Phase"1" trial,"all"compounds"tested,"except"naringenin" at" 10Z8M" and" PBS" generated" statistically" significantly" more" blood"vessels"prominent" in"the"surface"scar"(zZtest,"p<0.01)." "However,"there"were"no"significant"differences"between"the"other"four"compounds"tested.""Nicotinic"acid"has"been"previously"shown"to"be"proZangiogenic,"and"in"this"experiment"so"have"the"other"compounds"tested,"with"the"exception"of"naringenin"at"10Z8M.""Again,"it"is"thought"that"naringenin"at"this"concentration"is"biologically"inactive.""However,"increased"sample"size"may"yield"different"results,"but"results"gained"thus"far"are"encouraging.""Concerning" Phase" 2" of" the" experiments," paradoxical" results" were" gained" here"when" compared" to" the" Phase" 1" trial." " In" this" section," although" statistically" not"significant,"PBS"increased"wound"size"at"Day"3,"as"did"naringenin"x10Z8M"and"T1"x10Z7M" to" a" larger" degree." " In" the" Phase" 1" trial," it" was" T1" that" produced" the"largest" increase" in"wound" size," naringenin" being" less" effective," and" it" was" not"expected" that" the"PBS"control"would"exhibit" an" increased"wound"size." " Several"explanations"can"account"for"this." "The"first" is"that"there"was"a"degree"of"crossZcontamination" between" the" compounds" used;" however," every" conscious" effort"was" made" to" ensure" this" did" not" occur." " Secondly," the" experiments" were"undertaken" over" a" number" of"months" and" although" all" compounds"were" kept"refrigerated,," there" may" have" been" loss" of" biological" activity" with" some"compounds"and"increased"biological"activity"with"others"over"this"period.""Also,"although"not"appearing" infected"clinically," two"of" the"wounds"from"the"Phase"2"trial" displayed" pus" clusters" on" histological" examination." " A" factor" such" as" this"
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subclinical" infection" would" have" influenced" the" expected" results" in" a" negative"fashion"(Cerebrus"Animal"Report;"Appendix).""It" is"of"great"importance,"however,"that"both"T1"and"naringenin"at"their"highest"concentrations"had"a"greater"effect"on"wound"size"at"Day"3"than"nicotinic"acid,"a"proven"proZangiogenic"molecule."While"these"initial"results"are"encouraging,"the"numbers"of" animals" in" this"essential" trial" assay"are"quite" small." " It" is"proposed"that"a"similar"Phase"1"experiment"be"conducted,"this"time"with"greater"numbers"of"mice" (i.e.," 20"or"more)" in" each" treatment" group,"with" a" control" (PBS)" group"being" compared" with" both" T1" and" naringenin" at" varying" concentrations," and"there"being"a"once"only"application"of"each"compound.""This"would"allow"direct"comparison"of"these"compounds"and"collect"data"on"optimal"dosing"to"accelerate"healing,"but"not"induce"over"production"of"granulation"material"due"to"the"once"only" dosing." " Although" the" initial" wound" may" become" larger," without" the"repeated" application" downstream" events" in" wound" healing" may" not" be" over"stimulated" producing" what" appears" to" be" an" uncoordinated" healing" of" the"wound." " If" positive" results" were" gained" in" this" second" experiment," healingZimpaired" mice" would" be" the" next" logical" group" to" be" tested," with" nonZobese"diabetic"mice"would"be"ideal.""As" mentioned" above," angiogenesis" was" found" to" be" prominent" (statistically"significant)"at"the"surface"of"wounds"at"Day"12"with"all"compounds"tested,"except"for" PBS" and" naringenin" at" 10Z8M." " Although" blood" vessels" were" found" to" be"present" in"the"surface"of" the"scar," the"density"of"blood"vessels"at"Day"12"for"all"wounds"was" not" significantly" different." " This"would" agree"with" known"wound"
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healing"stages,"as"by"Day"12"angiogenesis"would"have"ceased"and"excess"blood"vessel"growth"receded.(60)"However,"histological"analysis"of"Phase"2"wounds"did"not" reveal" a" significant" change" in" wound" angiogenesis" at" Day" 3," indicating"perhaps"a"delayed"or"doseZaccumulated"response.""As"there"was"not"a"significant"change" in" blood" vessel" density" at" this" time" point" of" expected" maximal"angiogenesis," further," expensive" and" timeZconsuming" immunoZhistochemical"analyses"were"not"performed."Although"increase"in"blood"vessel"density"was"not"observed,"wound"size"did"increase," indicating"potential"early,"proZinflammatory"properties"of"the"compounds"tested."Neutrophil"influx"was"one"factor"measured"to"quantify"this"potential"result." "A"significant"increase"in"neutrophils"entry"into"some" wounds" was" observed" in" the" Phase" 1" trial," with" naringenin" at" 10Z6M"producing" a" significantly" higher" number" of" woundZassociated" neutrophils"(>30/hpf)" than" naringenin" at" 10Z8M" and" the" PBS" control" (p<0.05)," but" did" not"show" a" significant" difference" from" the" other" compounds" tested." " It," therefore,"may"be"a"property"of"naringenin"to"create"a"neutrophilic"wound"environment"by"a"currently"unknown"chemotactic"mechanism.""Although"two"animals"developed"infections,"identified"as"contained"pus"clusters"on"histological"examination,"these"findings"may"also"represent"potential"antibiotic"properties"of"naringenin"as" the"wounds"did"not"appear"to"be"clinically"infected.""Another" endpoint" measured" was" the" amount" of" collagen" deposited" in" the"wounds." " It" was" found" on" Day" 12" that" there" were" significant" differences" in"collagen" deposition," which" may" act" as" a" proxy" measurement" for" increased"fibroblast"activity.""This"activity"may"have"been"enhanced"by"T1"and"naringenin,"either"by"increasing"bFGF"levels"or"by"enhancing"the"biological"activity"of"bFGF..""
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T1" has" been" shown" previously" to" increase" endothelial" cell" and" fibroblast"proliferation" in# vitro,# this" effect" being" demonstrated" by" Prof." Parish’s" PhD"student," Ms" Farzaneh" Kordbacheh.(97)" Enhanced" collagen" deposition" would" be"advantageous," especially" in" chronic," difficult" to" heal" wounds" such" as" those"present" in" diabetics," pressure"ulcers," and"debilitated" and" elderly" patients." " For"example,"a"novel"application"could"potentially"be"the"use"of"T1"or"naringenin"in"conjunction"with" traditional" forms"of"skin"grafting" to" increase" the" likelihood"of"graftZtake." " The" ability" to" increase" skinZgraft" success" rates"would" decrease" the"need" for" repeated" procedures" for" patients" and" reduce" infection" risks" at" both"donor"and"graft"sites.""As" these" compounds" still" require" further" evaluation" and" based" on" the" finding"that" they" increase" granulation" tissue" formation," they"may" still" have" significant"proZangiogenic"activity"that"has"not"yet"been"demonstrated.""Besides"the"benefits"of"positive"angiogenesis,"derivatives"of"these"compounds"could"be"developed"that"may," conversely," have" antiZangiogenic" properties," thereby" acting" as" potential"therapeutic" agents" for" inhibiting" tumour" angiogenesis" and" enhancing" the"effectiveness"of"traditional"chemotherapeutic"agents.(142)""Although" the" overall" hypothesis" tested" in" this" thesis" was" not" proven," very"interesting"results"were"obtained,"many"of"which"are"significant,"especially"in"the"areas" of" angiogenesis," granulation" tissue" formation" and" collagen" deposition.""Further" research" is" thus" needed" to" clarify" the" functional" roles" of" these" new"compounds" that" could" potentially" heal" wounds" quicker." " Building" upon" work"
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conducted"in#vitro,"the"ability"of"these"compounds"to"potentiate"the"effects"of"the"already"potent"mitogen"and"wound"healing"agent,"bFGF,"cannot"be"ignored.(97)""
)
) )
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Chapter)6)Conclusions)and)Future)Studies:)
In"conclusion,"two"structurally"different"compounds"initially"trialled"at"the"John"Curtin" School" of"Medical"Research," T1" and"naringenin," have" been" shown" to" be"enhancers" of" bFGF" activity" in# vitro#and" have" yielded" promising" results" in# vivo.""The"hypothesis"tested"–"that"these"compounds,"when"applied"to"wounds,"would"increase"angiogenesis"and"accelerate"wound"healing"–"however,"was"not"proven.""In" fact," the" findings" were" quite" the" opposite" to" those" hypothesised" as" both"compounds"T1"and"naringenin"actually"caused"an"increase"in"wound"size"and"a"concomitant"decrease"in"wound"healing"rates.""This" decrease" in" wound" healing" rate" was" largely" due" to" the" formation" of"excessive"amounts"of"granulation"tissue"that"continued"throughout"the"duration"of" wound" healing." " For" example," T1" at" a" concentration" of" 10Z7M" resulted" in" a"residual"wound"size"greater"than"the"original"wound,"with"an"excess"amount"of"granulation"tissue"and"collagen"formation"being"present"on"histological"analysis.""This"result"does"correlate"with"previous" in#vitro#studies"performed"at"The" John"Curtin"School"of"Medical"Research"demonstrating"that"both"test"compounds"can"enhance" bFGFZinduced" proliferation" and" with" in# vivo# animal" studies" using"exogenous"application"of"bFGF"increasing"granulation"tissue"formation.(97,"113)"""Although" the" treated"wounds" did" not" heal" significantly" faster" than" the" control"group,"the"observed"increases"in"granulation"tissue"and"collagen"deposition"are"extremely" encouraging." " The" ability" of" a" substance," such" as" T1," when" applied"topically" to" increase" granulation" tissue" and" collagen" deposition" has" the" very"
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practical"potential"of"being"able"to"aid"or"accelerate"the"healing"of"wounds"that"are"notoriously"difficult"to"heal,"namely"diabetic"ulcers.""The" potential" for" these" compounds" to" be" novel" granulation" tissue" formation"accelerators" in" diabetic" wounds" certainly" warrants" further" investigation." " The"ability"of"these"compounds"to"accelerate"wound"healing"could"provide"numerous"savings"both"economically"and"in"the"human"costs"of"healthcare.""Further"studies"with" larger" trials" could"not" only" confirm" the" findings"of" this" research," but" also"find"optimal"dosage,"concentration"and"application"regimes"that"could"lead"to"the"development"of"vital"new"wound"healing"interventions."" "
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Appendix:)
Table)11:)Phase)1)Pixel)count)statistical)significance)differences)for)each)compound)compared)at)3)daily)intervals.)
 
        
Dependent Variable (I) Compound (J) Compound 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Day 0 pixel count Naragenin x10-8M PBS -98793.700* 2.906E4 .019 -188051.88 -9535.52 
T1 x10-8M 210159.400* 2.906E4 .000 120901.22 299417.58 
Nicotinic Acid x10-4M 199246.000* 2.906E4 .000 109987.82 288504.18 
Naragenin x10-6M 174418.900* 2.906E4 .000 85160.72 263677.08 
T1 x10-7M 188000.800* 2.906E4 .000 98742.62 277258.98 
PBS Naragenin x10-8M 98793.700* 2.906E4 .019 9535.52 188051.88 
T1 x10-8M 308953.100* 2.906E4 .000 219694.92 398211.28 
Nicotinic Acid x10-4M 298039.700* 2.906E4 .000 208781.52 387297.88 
Naragenin x10-6M 273212.600* 2.906E4 .000 183954.42 362470.78 
T1 x10-7M 286794.500* 2.906E4 .000 197536.32 376052.68 
T1 x10-8M Naragenin x10-8M -210159.400* 2.906E4 .000 -299417.58 -120901.22 
PBS -308953.100* 2.906E4 .000 -398211.28 -219694.92 
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Nicotinic Acid x10-4M -10913.400 2.906E4 1.000 -100171.58 78344.78 
Naragenin x10-6M -35740.500 2.906E4 1.000 -124998.68 53517.68 
T1 x10-7M -22158.600 2.906E4 1.000 -111416.78 67099.58 
Nicotinic Acid x10-4M Naragenin x10-8M -199246.000* 2.906E4 .000 -288504.18 -109987.82 
PBS -298039.700* 2.906E4 .000 -387297.88 -208781.52 
T1 x10-8M 10913.400 2.906E4 1.000 -78344.78 100171.58 
Naragenin x10-6M -24827.100 2.906E4 1.000 -114085.28 64431.08 
T1 x10-7M -11245.200 2.906E4 1.000 -100503.38 78012.98 
Naragenin x10-6M Naragenin x10-8M -174418.900* 2.906E4 .000 -263677.08 -85160.72 
PBS -273212.600* 2.906E4 .000 -362470.78 -183954.42 
T1 x10-8M 35740.500 2.906E4 1.000 -53517.68 124998.68 
Nicotinic Acid x10-4M 24827.100 2.906E4 1.000 -64431.08 114085.28 
T1 x10-7M 13581.900 2.906E4 1.000 -75676.28 102840.08 
T1 x10-7M Naragenin x10-8M -188000.800* 2.906E4 .000 -277258.98 -98742.62 
PBS -286794.500* 2.906E4 .000 -376052.68 -197536.32 
T1 x10-8M 22158.600 2.906E4 1.000 -67099.58 111416.78 
Nicotinic Acid x10-4M 11245.200 2.906E4 1.000 -78012.98 100503.38 
Naragenin x10-6M -13581.900 2.906E4 1.000 -102840.08 75676.28 
Day 3 pixel count Naragenin x10-8M PBS -146531.300* 4.207E4 .015 -275751.69 -17310.91 
! 131!
T1 x10-8M -16275.800 4.207E4 1.000 -145496.19 112944.59 
Nicotinic Acid x10-4M -42185.700 4.207E4 1.000 -171406.09 87034.69 
Naragenin x10-6M -111642.200 4.207E4 .157 -240862.59 17578.19 
T1 x10-7M -197393.600* 4.207E4 .000 -326613.99 -68173.21 
PBS Naragenin x10-8M 146531.300* 4.207E4 .015 17310.91 275751.69 
T1 x10-8M 130255.500* 4.207E4 .047 1035.11 259475.89 
Nicotinic Acid x10-4M 104345.600 4.207E4 .244 -24874.79 233565.99 
Naragenin x10-6M 34889.100 4.207E4 1.000 -94331.29 164109.49 
T1 x10-7M -50862.300 4.207E4 1.000 -180082.69 78358.09 
T1 x10-8M Naragenin x10-8M 16275.800 4.207E4 1.000 -112944.59 145496.19 
PBS -130255.500* 4.207E4 .047 -259475.89 -1035.11 
Nicotinic Acid x10-4M -25909.900 4.207E4 1.000 -155130.29 103310.49 
Naragenin x10-6M -95366.400 4.207E4 .412 -224586.79 33853.99 
T1 x10-7M -181117.800* 4.207E4 .001 -310338.19 -51897.41 
Nicotinic Acid x10-4M Naragenin x10-8M 42185.700 4.207E4 1.000 -87034.69 171406.09 
PBS -104345.600 4.207E4 .244 -233565.99 24874.79 
T1 x10-8M 25909.900 4.207E4 1.000 -103310.49 155130.29 
Naragenin x10-6M -69456.500 4.207E4 1.000 -198676.89 59763.89 
T1 x10-7M -155207.900* 4.207E4 .008 -284428.29 -25987.51 
Naragenin x10-6M Naragenin x10-8M 111642.200 4.207E4 .157 -17578.19 240862.59 
! 132!
PBS -34889.100 4.207E4 1.000 -164109.49 94331.29 
T1 x10-8M 95366.400 4.207E4 .412 -33853.99 224586.79 
Nicotinic Acid x10-4M 69456.500 4.207E4 1.000 -59763.89 198676.89 
T1 x10-7M -85751.400 4.207E4 .697 -214971.79 43468.99 
T1 x10-7M Naragenin x10-8M 197393.600* 4.207E4 .000 68173.21 326613.99 
PBS 50862.300 4.207E4 1.000 -78358.09 180082.69 
T1 x10-8M 181117.800* 4.207E4 .001 51897.41 310338.19 
Nicotinic Acid x10-4M 155207.900* 4.207E4 .008 25987.51 284428.29 
Naragenin x10-6M 85751.400 4.207E4 .697 -43468.99 214971.79 
Day 6 pixel count Naragenin x10-8M PBS -59832.000 3.999E4 1.000 -182671.95 63007.95 
T1 x10-8M -38129.500 3.999E4 1.000 -160969.45 84710.45 
Nicotinic Acid x10-4M -82976.800 3.999E4 .642 -205816.75 39863.15 
Naragenin x10-6M -156728.200* 3.999E4 .004 -279568.15 -33888.25 
T1 x10-7M -206910.500* 3.999E4 .000 -329750.45 -84070.55 
PBS Naragenin x10-8M 59832.000 3.999E4 1.000 -63007.95 182671.95 
T1 x10-8M 21702.500 3.999E4 1.000 -101137.45 144542.45 
Nicotinic Acid x10-4M -23144.800 3.999E4 1.000 -145984.75 99695.15 
Naragenin x10-6M -96896.200 3.999E4 .282 -219736.15 25943.75 
T1 x10-7M -147078.500* 3.999E4 .008 -269918.45 -24238.55 
T1 x10-8M Naragenin x10-8M 38129.500 3.999E4 1.000 -84710.45 160969.45 
! 133!
PBS -21702.500 3.999E4 1.000 -144542.45 101137.45 
Nicotinic Acid x10-4M -44847.300 3.999E4 1.000 -167687.25 77992.65 
Naragenin x10-6M -118598.700 3.999E4 .067 -241438.65 4241.25 
T1 x10-7M -168781.000* 3.999E4 .001 -291620.95 -45941.05 
Nicotinic Acid x10-4M Naragenin x10-8M 82976.800 3.999E4 .642 -39863.15 205816.75 
PBS 23144.800 3.999E4 1.000 -99695.15 145984.75 
T1 x10-8M 44847.300 3.999E4 1.000 -77992.65 167687.25 
Naragenin x10-6M -73751.400 3.999E4 1.000 -196591.35 49088.55 
T1 x10-7M -123933.700* 3.999E4 .046 -246773.65 -1093.75 
Naragenin x10-6M Naragenin x10-8M 156728.200* 3.999E4 .004 33888.25 279568.15 
PBS 96896.200 3.999E4 .282 -25943.75 219736.15 
T1 x10-8M 118598.700 3.999E4 .067 -4241.25 241438.65 
Nicotinic Acid x10-4M 73751.400 3.999E4 1.000 -49088.55 196591.35 
T1 x10-7M -50182.300 3.999E4 1.000 -173022.25 72657.65 
T1 x10-7M Naragenin x10-8M 206910.500* 3.999E4 .000 84070.55 329750.45 
PBS 147078.500* 3.999E4 .008 24238.55 269918.45 
T1 x10-8M 168781.000* 3.999E4 .001 45941.05 291620.95 
Nicotinic Acid x10-4M 123933.700* 3.999E4 .046 1093.75 246773.65 
Naragenin x10-6M 50182.300 3.999E4 1.000 -72657.65 173022.25 
Day 9 pixel count Naragenin x10-8M PBS -2792.500 3.026E4 1.000 -95743.77 90158.77 
! 134!
T1 x10-8M -55121.900 3.026E4 1.000 -148073.17 37829.37 
Nicotinic Acid x10-4M -112621.000* 3.026E4 .007 -205572.27 -19669.73 
Naragenin x10-6M -151504.500* 3.026E4 .000 -244455.77 -58553.23 
T1 x10-7M -221357.300* 3.026E4 .000 -314308.57 -128406.03 
PBS Naragenin x10-8M 2792.500 3.026E4 1.000 -90158.77 95743.77 
T1 x10-8M -52329.400 3.026E4 1.000 -145280.67 40621.87 
Nicotinic Acid x10-4M -109828.500* 3.026E4 .009 -202779.77 -16877.23 
Naragenin x10-6M -148712.000* 3.026E4 .000 -241663.27 -55760.73 
T1 x10-7M -218564.800* 3.026E4 .000 -311516.07 -125613.53 
T1 x10-8M Naragenin x10-8M 55121.900 3.026E4 1.000 -37829.37 148073.17 
PBS 52329.400 3.026E4 1.000 -40621.87 145280.67 
Nicotinic Acid x10-4M -57499.100 3.026E4 .942 -150450.37 35452.17 
Naragenin x10-6M -96382.600* 3.026E4 .036 -189333.87 -3431.33 
T1 x10-7M -166235.400* 3.026E4 .000 -259186.67 -73284.13 
Nicotinic Acid x10-4M Naragenin x10-8M 112621.000* 3.026E4 .007 19669.73 205572.27 
PBS 109828.500* 3.026E4 .009 16877.23 202779.77 
T1 x10-8M 57499.100 3.026E4 .942 -35452.17 150450.37 
Naragenin x10-6M -38883.500 3.026E4 1.000 -131834.77 54067.77 
T1 x10-7M -108736.300* 3.026E4 .011 -201687.57 -15785.03 
Naragenin x10-6M Naragenin x10-8M 151504.500* 3.026E4 .000 58553.23 244455.77 
! 135!
PBS 148712.000* 3.026E4 .000 55760.73 241663.27 
T1 x10-8M 96382.600* 3.026E4 .036 3431.33 189333.87 
Nicotinic Acid x10-4M 38883.500 3.026E4 1.000 -54067.77 131834.77 
T1 x10-7M -69852.800 3.026E4 .373 -162804.07 23098.47 
T1 x10-7M Naragenin x10-8M 221357.300* 3.026E4 .000 128406.03 314308.57 
PBS 218564.800* 3.026E4 .000 125613.53 311516.07 
T1 x10-8M 166235.400* 3.026E4 .000 73284.13 259186.67 
Nicotinic Acid x10-4M 108736.300* 3.026E4 .011 15785.03 201687.57 
Naragenin x10-6M 69852.800 3.026E4 .373 -23098.47 162804.07 
Day 12 pixel count Naragenin x10-8M PBS -3808.900 3.086E4 1.000 -98597.49 90979.69 
T1 x10-8M -14923.000 3.086E4 1.000 -109711.59 79865.59 
Nicotinic Acid x10-4M -86633.600 3.086E4 .104 -181422.19 8154.99 
Naragenin x10-6M -82542.300 3.086E4 .148 -177330.89 12246.29 
T1 x10-7M -186359.100* 3.086E4 .000 -281147.69 -91570.51 
PBS Naragenin x10-8M 3808.900 3.086E4 1.000 -90979.69 98597.49 
T1 x10-8M -11114.100 3.086E4 1.000 -105902.69 83674.49 
Nicotinic Acid x10-4M -82824.700 3.086E4 .145 -177613.29 11963.89 
Naragenin x10-6M -78733.400 3.086E4 .204 -173521.99 16055.19 
T1 x10-7M -182550.200* 3.086E4 .000 -277338.79 -87761.61 
T1 x10-8M Naragenin x10-8M 14923.000 3.086E4 1.000 -79865.59 109711.59 
! 136!
PBS 11114.100 3.086E4 1.000 -83674.49 105902.69 
Nicotinic Acid x10-4M -71710.600 3.086E4 .359 -166499.19 23077.99 
Naragenin x10-6M -67619.300 3.086E4 .492 -162407.89 27169.29 
T1 x10-7M -171436.100* 3.086E4 .000 -266224.69 -76647.51 
Nicotinic Acid x10-4M Naragenin x10-8M 86633.600 3.086E4 .104 -8154.99 181422.19 
PBS 82824.700 3.086E4 .145 -11963.89 177613.29 
T1 x10-8M 71710.600 3.086E4 .359 -23077.99 166499.19 
Naragenin x10-6M 4091.300 3.086E4 1.000 -90697.29 98879.89 
T1 x10-7M -99725.500* 3.086E4 .032 -194514.09 -4936.91 
Naragenin x10-6M Naragenin x10-8M 82542.300 3.086E4 .148 -12246.29 177330.89 
PBS 78733.400 3.086E4 .204 -16055.19 173521.99 
T1 x10-8M 67619.300 3.086E4 .492 -27169.29 162407.89 
Nicotinic Acid x10-4M -4091.300 3.086E4 1.000 -98879.89 90697.29 
T1 x10-7M -103816.800* 3.086E4 .021 -198605.39 -9028.21 
T1 x10-7M Naragenin x10-8M 186359.100* 3.086E4 .000 91570.51 281147.69 
PBS 182550.200* 3.086E4 .000 87761.61 277338.79 
T1 x10-8M 171436.100* 3.086E4 .000 76647.51 266224.69 
Nicotinic Acid x10-4M 99725.500* 3.086E4 .032 4936.91 194514.09 
Naragenin x10-6M 103816.800* 3.086E4 .021 9028.21 198605.39 
*. The mean difference is significant at the 0.05 level.      
)
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Table)12:)Phase)1)Histological)Score)Sheet)for)Naragenin)x10C8M)(NS)=)wound)not)sampled)correctly))
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Table)13:)Phase)1)Histological)Score)Sheet)for)PBS)
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Table)14:)Phase)1)Histological)Score)Sheet)for)T1)x)10C8M)
M
ou
se
&
Co
m
po
un
d&
sk
in
&u
lc
er
/e
ro
sio
n&
0=
ye
s;
1&
=n
o&
sc
ab
&0
=n
o&
;&1
=y
es
&
gr
an
ul
at
io
n&
tis
su
e&
0=
&n
o;
1&
=&
ye
s&
gr
an
ul
at
io
n&
tis
su
e&
1=
&su
rf
ac
e&
an
d&
de
ep
;&2
=&
ju
st
&
de
ep
&&
ca
vi
ty
&0
=n
o;
&1
=y
es
&
gr
an
ul
at
io
n&
tis
su
e&
0&
=&
no
&d
en
se
&fo
cu
s&1
=&
de
ns
e&
fo
cu
s&2
&=
&n
ot
&sa
m
pl
ed
&
su
be
pi
de
rm
al
&h
or
izo
nt
al
&m
at
ur
in
g&
sc
ar
&in
&c
en
tr
e&
0=
no
&;&
1=
ye
s&
sc
ar
&w
id
th
&(m
m
)&a
t&l
ev
el
&o
f&e
pi
de
rm
isD
&d
ist
an
ce
&
be
tw
ee
n&
in
ta
ct
&sk
in
&a
pp
en
da
ge
s&
sc
ar
&1
=&
th
in
&2
=&
th
ic
k&
w
ith
&v
isi
bl
e&
co
lla
ge
n&
tr
ic
hr
om
e&
st
ai
n&
0=
&n
o&
m
at
ur
e&
co
lla
ge
n&
1=
&
m
at
ur
e&
co
lla
ge
n&
tr
ic
hr
om
e&
D&c
ol
la
ge
n&
D&0
&=
&m
ed
iu
m
&1
&=
&a
&lo
t&2
&=
&
no
t&s
am
pl
ed
&
bl
oo
d&
ve
ss
el
s&p
re
se
nt
&in
&su
rf
ac
e&
sc
ar
&0
=n
o&
;&1
=&
ye
s&
bl
oo
d&
ve
ss
el
&p
ro
m
in
en
t&i
n&
su
rf
ac
e&
sc
ar
&(0
=&
no
,&
1=
ye
s)
&
de
ns
ity
&o
f&b
lo
od
&v
es
se
ls&
(&1
=&
lo
w
&D&
<2
0v
es
se
ls&
hp
f;&
2=
&m
ed
iu
m
D2
0D
50
&&3
=&
hi
gh
&>
50
&v
es
se
ls/
hp
f)&
&
nu
m
be
r&o
f&n
eu
tr
op
hi
ls&
no
t&a
ss
oc
ia
te
d&
w
ith
&
fo
re
ig
n&
m
at
er
ia
l&0
=<
3h
pf
&1
=<
20
hp
f;&
2=
20
D
30
hp
f,&
3=
&&>
30
hp
f&
nu
m
be
r&o
f&n
eu
tr
op
hi
ls&
&a
ss
oc
ia
te
d&
w
ith
&fo
re
ig
n&
m
at
er
ia
l&0
=<
3h
pf
,&1
=<
20
hp
f;&
2=
20
D3
0h
pf
,&3
=&
&
>3
0h
pf
&
fo
re
ig
n&
m
at
er
ia
l&0
=y
es
;1
&=
no
&
ty
pe
&o
f&f
or
ei
gn
&m
at
er
ia
l&1
=&
ve
ge
ta
bl
e;
&
2=
be
dd
in
g,
&3
=&
ha
ir&
4=
ot
he
r&
ca
lc
ifi
ca
tio
n&
0=
no
;&1
=y
es
&
CO
M
M
EN
T&
C1& T1&x&10D8M& 0& 0& 1& 1& 0& 1& 0& 0.4& 1& 1& 1& 1& 1& 1& 3& 0& 0& 1& 0&
Neutrophil
s&away&
from&scar&
C2& && 0& 1& 1& 1& 0& 0& 1& 2.3& 2& 1& 1& 1& 1& 1& 1& 0& 1& 3& 0& &&
C3& && 0& 0& 1& 1& 0& 0& 1& 2.3& 2& 1& 1& 1& 1& 1& 2& 0& 0& 3& 0& &&
C4& && 0& 0& 1& 1& 0& 0& 1& 1.5& 2& 1& 0& 1& 1& 1& 2& 0& 0& 3& 0& &&
C5& && 0& 0& 1& 1& 0& 0& 1& 1.3& 2& 1& 0& 1& 1& 1& 3& 3& 1& 3& 0& &&
)
)
)
)
! 140!
Table)15:)Phase)1)Histological)Score)Sheet)for)Nicotinic)Acid)(NS)=)wound)not)sampled)correctly))
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Table)16:)Phase)1)Histological)Score)Sheet)for)Naragenin)x10C6M)(NS)=)wound)not)sampled)correctly))
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Table)17:)Phase)1)Histological)Score)Sheet)for)T1)x10C7M)
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&
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&
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Table)18:))Analysis)of)Phase)1)Compounds)Tested)and)Granulation)Tissue)Level)in)Wounds)at)Day)12)
)
Compound)) Granulation)Tissue)Level) Total)
No.)(%))Surface)and)Deep)
No.)(%))
Deep)only)
No.)(%))PBS! 0!(0%)! 5!!(100%)! 5!!(100%)!Nicotinic!acid!:10:4M! 0!(0%)! 5!!(100%)! 5!!(100%)!Naringenin!:!10:6M! 0!(0%)! 5!!(100%)! 5!!(100%)!Naringenin!:!10:8M! 0!(0%)! 4!(100%)! !4!!(100%)*!T1!:!10:7M! 5!!(100%)! 0!(0%)! 5!!(100%)!T1!:!10:8M! 5!!(100%)! 0!(0%)! 5!!(100%)!*One!wound!for!one!of!the!Naringenin!(10:8M)!series!was!not!sampled!due!to!inadequate!surgical!excision!and!was!not!included!in!the!statistical! analysis.! !Both!T1! compounds! resulted! in! significant! surface! and!deep!granulation! compared! to! all! other! compounds! (p!<!0.01).!!!
)
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Table)19:))Analysis)of)Phase)1)Compounds)Tested)and)Granulation)Tissue)Density)in)Wounds)at)Day)12)
)
Compound)) Granulation)Tissue)Density) Total)
No.)(%))Dense)
No.)(%))
Not)Dense)
No.)(%))PBS! 5!!(100%)! 0!(0%)! 5!!(100%)!Nicotinic!acid!:!10:4M! 3!(60%)! 2!(40%)! 5!!(100%)!Naringenin!:!10:6M! 3!(60%)! 2!(40%)! 5!!(100%)!Naringenin!:!10:8M! 0!(0%)! 4!(100%)! !4!!(100%)*!T1!:!10:7M! 1!(20%)! 4!(80%)! 5!!(100%)!T1!:!10:8M! 1!(20%)! 4!(80%)! 5!!(100%)!*One!wound!for!one!of!the!Naringenin!(10:8M)!series!was!not!sampled!due!to!inadequate!surgical!excision!and!was!not!included!in!the!statistical!analysis.!!Wounds!from!mice!treated!with!PBS!had!significantly!more!denser!granulation!tissue!foci!(p!=!0.024).!!
)
)
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Table)20:))Analysis)of)Phase)1)Compounds)Tested)and)Trichrome)Collagen)Density)in)Wounds)at)Day)12)
)
Compound)) Trichrome)collagen)density) Total))
No.)(%))High)
No.)(%))
Medium)
No.)(%))PBS! 2!(40%)! 3!!(60%)! 5!!(100%)!Nicotinic!acid!x10:4M! 0!(0%)! 5!(100%)! 5!!(100%)!Naringenin!x10:6M! 3!(60%)! 2!(40%)! 5!!(100%)!Naringenin!x10:8M! 0!(0%)! 4!(100%)! 4!!(100%)*!T1!x10:7M! 5!(100%)! 0!(0%)! 5!!(100%)!T1!x10:8M! 3!(60%)! 2!(40%)! 5!!(100%)!*One!wound! for! one! of! the!Naringenin! x10:8M! series! not! sampled! due! to! inadequate! surgical! excision! and!was! not! included! in! the!statistical!analysis.!!Wounds!from!mice!treated!with!T1!at!10:7M!had!a!significantly!higher!Trichrome!density!(p!=!0.009).!
)
)
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Table)21:))Analysis)of)Phase)1)Compounds)Tested)and)Blood)Vessel)Surface)Scar)Prominence)in)Wounds)at)Day)12)
)
Compound)) Blood)vessels)prominent)in)
surface)scar)
Total))
No.)(%))
Yes)
No.)(%))
No)
No.)(%))PBS! 0!(0%)! 5!(100%)! 5!(100%)!Nicotinic!acid!(10:4M)! 5!(100%)! 0!(0%)! 5!(100%)!Naringenin!(10:6M)! 5!(100%)! 0!(0%)! 5!(100%)!Naringenin!(10:8M)! 0!(0%)! 4!(100%)! !!4!(100%)*!T1!(10:7M)! 5!(100%)! 0!(0%)! 5!(100%)!T1!(10:8M)! 5!(100%)! 0!(0%)! 5!(100%)!*One!wound!for!one!of!the!Naringenin!(10:8M)!series!was!not!sampled!due!to!inadequate!surgical!excision!and!was!not!included!in!the!statistical!analysis.!!All!the!compounds!except!Naringenin!at!10:8M!and!PBS!generated!statistically!significantly!more!blood!vessels!in!the!surface!scar!(p!<!0.01).)
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Table)22:))Analysis)of)Phase)1)Compounds)Tested)and)Number)of)Neutrophils)not)Associated)with)Foreign)Material)in)Wounds)
at)Day)12)
)
Compound)) Number)of)neutrophils)not)associated)with)foreign)
material)per)high)power)field)(hpf))
Total))
No.)(%))
<3/hpf)
3–19/hpf)
20–
30/hpf)
>30hpf)
PBS! 5!(100%)! 0!(0%)! 0!(0%)! 0!(0%)! 5!(100%)!Nicotinic!Acid!(10:4M)! 1!(20%)! 1!(20%)! 2!(40%)! 1!(20%)! 5!(100%)!Naringenin!(10:6M)! 0!(0%)! 2!(40%)! 0!(0%)! 3!(60%)! 5!(100%)!Naringenin!(10:8M)! 3!(60%)! 0!(0%)! 1!(20%)! 0!(0%)! 4!(100%)*!T1!(10:7M)! 2!(40%)! 2!(40%)! 0!(0%)! 1!(20%)! 5!(100%)!T1!(10:8M)! 0!(0%)! 1!(20%)! 2!(40%)! 2!(40%)! 5!(100%)!*One!wound!for!one!of!the!Naringenin!(10:8M)!series!was!not!sampled!due!to!inadequate!surgical!excision!and!was!not!included!in!the!statistical!analysis.!!Naringenin!at!10:6M!produced!significantly!higher!>30/hpf!neutrophils!(p!=!0.043).!!!
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Table)23:))Analysis)of)Phase)1)Compounds)Tested)Demonstrating)Mature)SubCepidermal)Scar)at)Day)12)
)
Compound)) Mature)SubCepidermal)Scar) Total))
No.)(%))Yes)
No.)(%))
No)
No.)(%))PBS! 5!(100%)! 0!(0%)! 5!(100%)!Nicotinic!acid!(10:4M)! 5!(100%)! 0!(0%)! 5!(100%)!Naringenin!(10:6M)! 5!(100%)! 0!(0%)! 5!(100%)!Naringenin!(10:8M)! 4!(100%)! 0!(0%)! !!4!(100%)*!T1!(10:7M)! 2!(40%)! 3!(60%)! 5!(100%)!T1!(10:8M)! 4!(80%)! 1!(20%)! 5!(100%)!*One!wound!for!one!of!the!Naringenin!(10:8M)!series!was!not!sampled!due!to!inadequate!surgical!excision!and!was!not!included!in!the!statistical!analysis.!!T1!at!10:7M!produced!significantly!less!mature!sub:epidermal!scar!(p!=!0.04).!!!
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Table)24:)Phase)2)PixelCcount)Statistical)Analysis 
Descriptives 
  
N Mean Std. Deviation Std. Error 
95% Confidence Interval for Mean 
Minimum Maximum   Lower Bound Upper Bound 
Day 0 pixel count 1 5 1.60E5 42007.531 1.879E4 107437.16 211755.64 103203 214250 
2 5 1.42E5 28230.323 1.262E4 107341.82 177446.98 119442 179767 
3 5 1.68E5 61837.029 2.765E4 91098.59 244660.21 106781 261126 
Total 15 1.57E5 44103.459 1.139E4 132199.72 181047.08 103203 261126 
Day 3 pixel count 1 5 1.91E5 77129.236 3.449E4 94984.81 286521.99 113083 282361 
2 5 2.30E5 36199.857 1.619E4 184588.34 274484.46 168107 262578 
3 5 2.38E5 93749.301 4.193E4 121899.07 354709.33 118870 335834 
Total 15 2.20E5 71011.356 1.834E4 180206.56 258856.11 113083 335834 
&
ANOVA&overleaf.&
&
&
&
&
&
&
&
&
&
&
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ANOVA 
 Sum of Squares df Mean Square F Sig. 
Day 0 pixel count 
Between Groups 
1690003530.00
0 
2 845001765.000 .397 .681 
Within Groups 
25541607679.6
00 
12 
2128467306.63
3 
  
Total 
27231611209.6
00 
14 
   
Day 3 pixel count 
Between Groups 
6403456644.13
3 
2 
3201728322.06
7 
.599 .565 
Within Groups 
64193120165.2
00 
12 
5349426680.43
3 
  
Total 
70596576809.3
33 
14 
   
&
There&was&no&significant&difference&between&the&mean&pixel&counts&on&Day&0&and&Day&3&among&the&wounds&treated&with&different&compounds&(p&>&0.05).&!
) )
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Table)25:)Phase)2)Histological)Score)Sheet)
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1& PBS& 1& 1& 2& 0& 0& 0& 0& 1& 1& 0& 1&
&
&&
2& Naragenin&x10D6M& 0& 1& 1& 0& 0& 0& 0& 1& 0& 0& 1&
&
&&
3& T1&x10D7M& 1& 1& 1& 1& 0& 0& 0& 1& 0& 0& 1&
&
&&
4& Naragenin&x10D6M& 0& 1& 1& 1& 0& 0& 0& 1& 0& 0& 1&
&
&&
5& PBS& 1& 1& 2& 1& 0& 0& 0& 1& 1& 0& 1&
&
&&
6& T1&x10D7M& 1& 1& 1& 1& 0& 0& 0& 1& 3& 3& 0& 4&
PUS&
CLUSTERS&
7& Naragenin&x10D6M& 0& 1& 2& 0& 0& 0& 0& 1& 2& 2& 0& 1& &&
8& T1&x10D7M& 0& 1& 2& 0& 0& 0& 0& 1& 1& 0& 1&
&
&&
9& PBS& 0& 1& 2& 0& 0& 0& 0& 1& 1& 0& 1&
&
&&
10& T1&x10D7M& 1& 1& 1& 1& 0& 0& 0& 1& 1& 2& 1&
&
&&
11& Naragenin&x10D6M& 0& 1& 2& 0& 0& 0& 0& 1& 2& 1& 0& 1& &&
12& PBS& 1& 1& 2& 1& 0& 0& 0& 1& 1& 3& 0& 4& &&
13& T1&x10D7M& 1& 1& 1& 1& 0& 0& 0& 1& 0& 0& 1&
&
&&
14& PBS& 1& 1& 2& 0& 0& 0& 0& 1& 0& 2& 0& 4&
PUS&
CLUSTERS&
15& Naragenin&x10D6M& 1& 1& 1& 1& 0& 0& 0& 1& 2& 0& 1& && &&
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